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Abstract 
Therapeutic and Diagnostic Applications of Ultrasound Contrast Media 
for Breast, Ovarian and Skin Cancers 
Kelleny Oum 
Margaret A. Wheatley, PhD 
 
 
Using contrast enhanced ultrasound, molecular markers of disease can be 
noninvasively imaged. This method is dependent on the administration of a microbubble 
contrast agent (CA) made site-targeted by the surface attachment of engineered peptides 
or antibodies that bind to the disease related receptor molecules. The microbubbles 
selectively retained by the tissues can then be detected using ultrasound.  The overall 
objective of this research is to engineer the surface poly (DL-lactic acid) (PLA) and poly 
(DL-lactic-co- glycolic acid) (PLGA)  based microbubble CAs to facilitate efficient 
targeting of molecular markers in vitro that can potentially enable the early detection and 
treatment of breast, skin and ovarian cancers.   
To enhance the diagnostic application of CAs, this research demonstrated that: (1) 
echogenic microbubbles can be created with a carboxyl containing surfactant (PEMA) 
which allowed more targeting ligand to be conjugated to its surface than that of 
microbubbles made with a hydroxyl containing surfactant (PVA) (p<0.05), although it 
did not improve cellular targeting ability (p>0.05); (2) a method of physically 
incorporating a lipid-ligand conjugate (DSPE-PEG-biotin) can be achieved for attaching 
a variety of targeting ligands; (3) rough-surfaced PLGA 50:50 based microbubbles have a 
significantly greater cellular attachment than smooth surface microbubbles once ligated 
with GRGDS (p<0.05); (4) an ultrasound CA targeting CA-125 receptors using anti-CA-
 xiii
125 antibodies bound to the surface of the microbubbles created significant CA 
attachment (p<0.05) to OVCAR-3 cells.  
To explore the potential for therapeutic applications a novel ultrasound CA that 
acts via signal transduction was examined. A TRAIL-modified CA induced a signaling 
cascade resulting in apoptosis in breast, ovarian and skin cancer cells. Furthermore, 
TRAIL-modified CA exhibited significantly greater apoptotic effects when combined 
with a proteasome inhibitor Velcade in melanoma cells (p<0.05). 
The various aspects of this research were conducted with the intent of combining 
them with drug delivery in future applications. This would bring together the advantages 
of site-targeting, drug delivery, and signal transduction with the benefits of ultrasound 
imaging to effect a significant improvement in cancer detection and treatment.
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1. INTRODUCTION 
 
 
Using contrast enhanced ultrasound, molecular markers of disease can be 
noninvasively imaged. This method is dependent on the administration of microbubble 
contrast agents (CA) targeted by the surface attachment of engineered ligands or 
antibodies that bind to the disease related receptor molecules[1] . The microbubbles 
selectively retained by the tissues can then be detected using ultrasound [2, 3].   
Since CAs have the potential to be tailored with a variety of targeting vectors, this 
technology has far ranging potential for the detection, monitoring and treatment of 
numerous diseases. Specifically, detection of αv-integrin expression in tumor neovessels 
may be particularly advantageous, since these integrins play a functional role in 
angiogenesis and have been identified as a marker of metastatic potential in tumors [4]. 
Modified CAs have the potential to elicit bioeffects such as apoptosis. Targeted CAs 
could also be used for early detection of other malignancies such as ovarian cancer. In 
addition, the CA can be loaded with a bioactive compound such as an anti-cancer drug. 
To date, investigations of molecularly targeted ultrasound contrast agents have 
primarily focused on the development of lipid-coated perfluorocarbon microbubble 
system [5-8]. However, there is a lack of research on the targeting of polymeric, in 
particular poly-α hydroxy acids such as poly(lactic acid) (PLA) and poly(lactic-co-
glycolic acid) (PLGA) - shelled, microbubble CAs. Polymeric microbubbles bear the 
advantage of being more stable and have a more controllable degradation than their lipid-
coated counterparts.  The rigid shell can also interact with ultrasound and the 
environment in a different way, and can carry a more substantial drug payload.  
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Combination of the two modalities (targeting and drug loading) in the form of a targeted 
drug carrier would have the advantage of being able to deliver a sustained dose of drug 
directly at the target site, with the added possibility of enhanced delivery triggered by 
ultrasound. 
 We have developed a double emulsion method for the fabrication of hollow, 
echogenic PLGA microbubbles[9]. PLGA is a well-known FDA approved biodegradable 
polymer for in vivo applications [10]. This polymer breaks down by hydrolytic 
degradation of its backbone, and has exposed carboxyl groups available for chemical 
modification with targeting vectors. Its nature allows the adjustable loading of drugs into 
its surface, shell or core. Overall, surface engineered PLGA CAs represent a highly 
adaptable cancer targeting system applicable to a variety of cancers by the addition of 
moieties that target specific entities on cell membranes with the added benefit of real-
time ultrasound monitoring capabilities.  
 
1.2 Thesis Objectives 
 
The overall goal of this research is the in vitro development of PLA and PLGA based 
microbubble CAs that facilitate targeting to molecular markers enabling the early 
detection and potentially treatment of malignancies.   Toward this goal we utilize a 
strategy composed of the following three Specific Aims: 
 
Specific Aim 1  To characterize, optimize and develop methods of making 
biodegradable polymer contrast agents that have the capacity for carrying targeting 
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vectors and to assess cell attachment capabilities of the CA to breast cancer cells in 
vitro. 
¾ 1. We have previously developed hollow echogenic microcapsules with 
demonstrated ability to carry the targeting ligand gly-arg-gly-asp-ser (GRGDS) with 
varying density. From these results we have chosen poly (lactic acid) PLA as a 
suitable carrier polymer, however the most uniform capsules to date are prepared 
from end-capped polymer, which presents fewer reactive groups on the surface 
available for chemical modification with ligand. We hypothesize that we can further 
functionalize the surface of the PLA by enhancing the number of carboxyl groups 
available for chemical conjugation. A surfactant, which coats the microbubbles with 
active carboxyl groups, polyethylene maleic acid (PEMA), will be synthesized and 
characterized. PEMA will be used to replace our original surfactant poly (vinyl 
alcohol) (PVA) and resultant CAs will be evaluated in terms of morphology, 
echogenicity, stability, and ligand carrying capacity (using flow cytometry analysis). 
Static cell attachment studies will be performed using MDA-MB-231 breast cancer 
cells and GRGDS modified CAs made with PEMA. Microbubble/cell adherence will 
be assessed at various time points with unmodified CAs as controls using light 
microscopy.  
¾ 2. Another approach is the physical incorporation of lipid-ligand conjugates: this 
approach has been primarily explored in the formation of lipid-based contrast agents, 
and more recently with solid polymer microspheres but has not yet been extended to 
polymer-based CAs [11]. This technique allows the insertion of a lipid-poly 
(ethylene glyol) (PEG) - functional group into the shell of the microbubbles. We 
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hypothesize that by the addition of a lipid-PEG-biotin into our first emulsion we will 
be able to create microbubbles with incorporated lipid-PEG-biotin that can be further 
functionalized with targeting ligands. To achieve this, microbubbles will be 
synthesized, characterized acoustically and morphologically, and surface density of 
functional groups will be qualitatively assessed by fluorescence intensity.  
¾ 3. The effect of microbubble morphology on cellular attachment is also a 
consideration in targeting. We hypothesize that by changing parameters in the double 
emulsion fabrication method we can produce bubbles that are of a rough texture and 
may have an enhanced binding to cancer cells once ligated. PLGA bubbles with 
rough surfaces may hold a different amount of peptide and may have an altered 
presentation of the peptide to cellular integrin receptors compared to smooth 
surfaced bubbles made of the same polymer. To achieve this we will vary 
aqueous/organic phase ratios, porogen amounts, surfactant molecular weights, 
homogenization and evaporation speeds during fabrication. The resulting smooth and 
rough microbubbles will then be evaluated for morphology, size and acoustic 
properties prior to being conjugated with GRGDS or control peptides using a 
carbodiimide reaction. The static attachment to MDA-MB-231 breast cancer cells 
will be assessed. 
 
Specific Aim 2 Produce a novel bioactive ultrasound CA that elicits signal 
transduction, using TRAIL/apoptosis as a model. 
¾ The hypothesis is that the majority of cell surface receptors act as transducers of 
signals that are external to the cell to trigger an intracellular cascade, and that this 
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mechanism can be utilized to trigger a desired effect when a targeted contrast agent 
interacts with a cell surface receptor. Specifically, by conjugating the ligand tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) to the microbubble 
surface, cellular apoptosis can be achieved once the TRAIL-microbubbles bind to 
death receptors on the cell surface. TRAIL stimulates the tumor necrosis factor 
receptors, death receptor 4 and 5 (DR4 and DR5) which cause apoptosis in an 
extrinsic manner by triggering a capsase cascade within the cell. To achieve this, 
another method of conjugation will be investigated. A maleimide conjugation 
scheme utilizing a N-[ß-Maleimidopropionic acid] hydrazide (BMPH) 
crosslinker/spacer will be developed and used to conjugate TRAIL to the surface of 
the microbubbles. These TRAIL-microbubbles will then be incubated on TRAIL-
sensitive breast cancer, ovarian cancer and melanoma cell models. Controls include 
incubation with unmodified bubbles, TRAIL only and microbubbles with adsorbed 
TRAIL. Experiments examining the synergistic effect of proteasome inhibitors and 
TRAIL-microbubbles on cellular apoptosis will also be performed.  Qualitative 
evaluation of apoptosis for each CA will be performed using a fluorescent apoptosis 
assay and fluorescent microscopy or flow cytometry. This novel concept has not 
been reported for any ultrasound CA currently in development.  
 
Specific Aim 3 Produce a targeted contrast agent with the potential  for early 
detection of ovarian cancer cells 
¾  Ovarian cancer (OC) accounts for approximately 3% of all cancers in women and is 
the 5th leading cause of cancer-related death among women in the United States. 
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Ovarian cancer has the highest mortality of all cancers of the female reproductive 
system. This reflects a lack of both early symptoms and proven ovarian cancer 
screening tests. Thus, ovarian cancer is often diagnosed at an advanced stage, after 
the cancer has spread beyond the ovaries. Development of a contrast agent to target 
OC has not been reported to date. Contrast enhanced ultrasound is an ideal non-
invasive early detection method for OC.  We hypothesize that by coupling anti-CA-
125 antibodies (Ab) specific to the naturally upregulated CA-125 receptor present in 
ovarian cancer to our microbubbles, we can develop an ovarian cancer detection 
model using an ultrasound contrast agent platform. The OC targeted agent is being 
developed for intraperitoneal injection for detection of surface lesions or for 
targeting by extravasation through leaky tumor vasculature.  In order to find the 
optimal method for antibody immobilization, several methods will be examined. The 
first two methods include antibody fragmentations to create free thiol groups for 
conjugation to the microbubble surface at the antibody’s hinge region. Alternatively, 
a conjugation strategy using full anti-CA-125 antibodies conjugated to the 
microbubble surface by carbodiimide chemistry will be evaluated. Live OVCAR-3 
ovarian cancer cell attachment assays will be performed to visually assess 
microbubble adhesion/cell at various time points. CA-125 receptor negative cells, 
A2058 melanoma cells, will be used as a control.   
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2. BACKGROUND AND LITERATURE REVIEW  
 
 This chapter presents background information along with a review of the pertinent 
literature on (1) ultrasound imaging, (2) ultrasound contrast agents with a focus on 
targeting and PLGA microbubbles (3) polymeric surface modification for attachment of 
bioactive compounds, and (4) cancer targeting and treatment.  
 
2.1 Ultrasound Imaging 
Ultrasound is a medical imaging technique that uses sound waves and their echoes 
to create images. The major benefits of this technique are that it is safe, non-invasive, 
portable, gives information in real-time, can be used for many different types of 
procedures, and is relatively inexpensive compared to x-ray and magnetic resonance 
imaging (MRI). 
In diagnostic ultrasound, a transmitted sound wave (2MHz - 17 MHz) travels into 
the body and at the boundary between tissues (e.g. between fluid and soft tissue, soft 
tissue and bone) some of the sound waves get reflected back to the probe due to an 
impedance mismatch. Some of the signal is scattered, some is absorbed as heat and some 
travels on further until being reflected by another boundary.  Impedance is the product of 
density and the speed of sound through a material. As the difference between the 
impedance for two media increases, the more signal will be reflected.  This reflected 
signal, also known as an echo, returns to the transducer and is used to produce ultrasound 
images. To produce the images, a transducer receives the reflected ultrasound signal from 
the tissue and converts these mechanical waves into electrical signals. Transducers are 
usually made from piezoelectric or ferroelectric materials that change their thickness and 
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shape as a voltage is applied across them, and conversely create electrical potential when 
they are deformed. After being converted by the transducer, the ultrasound information is 
then processed by a receiver that alters the signal to remove noise and to adjust signals 
from deeper reflections for attenuation [12] The signals are then converted for display. 
 
2.2 Ultrasound Contrast Agents 
 As with any imaging modality, there are limitations to the types of tissues that can 
be imaged with ultrasound. To increase diagnostic yield, contrast agents have been 
introduced to ultrasonography. Contrast agents usually consist of gas-filled microbubbles. 
The microbubbles act as signal enhancers, and operate by the basic mechanism present in 
all cases of diagnostic ultrasound, and in this case that the backscattered signal intensity 
is proportional to the change in acoustic impedance between the blood and the gas inside 
the bubbles [13]. In other words, a contrast agent provides an impedance mismatch where 
one did not exist or was not large enough to generate a visible signal. At the blood/gas 
interface the difference in acoustic impedance is very high; there is a perfect reflection of 
the incident sound wave, though not all the signal will return to the transducer due to 
scattering in other directions. Contrast agents should increase backscattered signal as 
much as possible without increasing the attenuation of the tissue.  
A bubble at resonance has three orders of magnitude greater backscatter cross 
section, a measure of echogenicity, compared to a non resonating bubble [14]. It is 
desirable to maximize the resonant properties in the design of a contrast agent which 
takes into account size. The microbubbles must be small enough to cross the capillary 
bed (<7.5 microns) and the resonant frequency depends inversely on bubble diameter. It 
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is a fortuitous coincidence that the resonance frequency of free microbubbles 1–7 
microns in diameter lies within the traditional 2–15 MHz medical ultrasound range. The 
amplitude of the contrast agent oscillations (and hence the scattering effect) is thus 
maximized [15].  
The ability to produce sustained signals from contrast agents depends on the 
stability of the gas core, and the existence of mechanisms to prevent coalescence.  
Longevity is enhanced in bubbles by modification of the gas content and provision of a 
stabilizing shell.  According to Epstein-Plesset models, gas loss from a free bubble is 
dependent on its size, the surface tension, and gas characteristics such as solubility and 
diffusion capacity [16]. Thus, the stability of contrast agents can be improved by using 
gases with low diffusion coefficients and low solubility in water/blood. Commonly used 
gases include air, nitrogen, sulfur hexafluoride and perflurocarbons, although air and 
nitrogen tend to be too soluble and low molecular weight [17]. The encaspsulation of 
bubbles with shells made of proteins, lipids or polymers are also used to enhance 
stability, by reducing outward diffusion, reducing surface tension, and controlling 
microbubble size and coalescence [17]. 
Currently, there are three agents approved in the United States for clinical use in 
cardiology; Optison (GE Healthcare, Princeton, NJ), a perfluoropropane-filled agent with 
a phospholipid shell, Imagent (Alliance Pharmaceutical, San Diego, CA), a perflexane 
lipid shelled agent, and Definity (Lantheus Medical Imaging, North Billerica, MA), a 
perflutren lipid shelled agent. Several other microbubble contrast agents have been 
approved in Europe and Canada [18], including Sonovue (Bracco, Princeton, NJ), a 
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sulfahexafluoride filled phosplolipid shelled agent and Levovist (Schering, Kenilworth 
NJ), an air filled fatty acid shelled agent[19] .  
 
2.3 Polymeric Ultrasound Contrast Agents  
2.3.1 PLGA  
Many material choices have in the past been investigated for the formulation of 
microbubbles, including, polysaccharides (such as starch, alginate, and agarose), proteins 
(such as gelatin, and albumin), fats and fatty acids (such as palmitic and stearic acid), 
lipids and polymers [20]. 
Polymers have quickly become a widely applied material in the field of 
biomedical engineering and materials science. Poly (lactic – co – glycolic acid) (PLGA) 
polymers can be easily modified and processed, and their mechanical properties can be 
controlled. PLGA has been FDA approved for use in sutures and drug delivery devices 
[10]. The most important features of PLGA are that it is biodegradable and 
biocompatible.  It degrades into lactic acid and glycolic acid. Lactic acid enters the 
tricarboxylic acid cycle and is metabolized and eliminated from the body as carbon 
dioxide and water. Glycolic acid is either excreted unchanged in the kidney or it enters 
the tricarboxylic acid cycle and is eliminated as carbon dioxide and water [10]. The in 
vivo degradation of PLGA is affected by several properties, among them glass transition 
temperature (Tg), molecular weight, and crystallinity [21]. The porosity of a polymer 
construct (including capsules) will affect the degradation rate.  As porosity increases, so 
does the surface area in contact with fluid and thus, the greater amount of area that can 
undergo degradation.  Consequently, the greater the porosity, the faster the rate of 
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degradation. The structure of PLGA and the homo polymer PLA are depicted in figure 
2.1. 
A B
 
Figure 2.1: Chemical Structures of (A) Poly (lactic acid) and (B) Poly (lactic-co-glycolic acid) 
 
2.3.2 Emulsions 
One method to produce microcapsules is emulsification [9]. An emulsion is a mixture 
of 2 immiscible liquids. The solvent evaporation technique has been used to produce 
microbubbles of PLA and PLGA. These polymers have been studied extensively due to 
their biocompatibility. A polymeric solution is dispersed and emulsified in an aqueous 
continuous phase to form droplets and the organic solvent must evaporate at the air/water 
interface. During solvent evaporation, the microcapsules start to harden and can be 
collected [22]. This method has been used to prepare PLA and PLGA microbubbles with 
many different drugs such as anticancer drugs, narcotic agents, local anesthetics and 
steroids [22]. 
 In a conventional O/W encapsulation there is an emulsification of an organic 
polymeric solution in an aqueous continuous phase. The emulsion is produced by 
agitating the two immiscible liquids and dispersing them via high shear with the use of 
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propeller blades, homogenization, microfluidization, or sonication [23, 24]. The greater 
the shear produced, the smaller the particles. Also, there is an influence of type and ratio 
of surfactant, rate of solvent evaporation, solvent type, agitation rate, and polymer 
molecular weight on the physiochemical characteristics. Sansdrap et al. found that 
microparticles became smaller when stirring rate was increased and that the mean 
diameter of the microsphere decreased as the volume of solvent increased [25]. 
In multiple emulsion systems such as a water-oil-water (W/O/W), the preparation 
conditions have a significant impact on the morphology and porosity of the micros 
bubbles [22]. Investigating the effects of buffers or salts added to the internal and/or 
external aqueous solutions on the properties of somatostatin acetate-containing PLA 
microspheres, Hermann et al. [26] found that adding buffers or salts to the internal phase 
resulted in porous microspheres and that adding them to the external phase resulted in a 
dense homogenous polymer matrix. To investigate the effects of volume of the inner 
water phase on the internal and external structure of the polymer microspheres 5 batches 
of bovine serum albumin in PLGA microspheres were prepared using 1 to 22.7% inner 
water volume [27] and it was found that an initial inner aqueous phase volume fraction of 
5.6% produced hollow microspheres with a dense nonporous polymer shell. However, 
with an initial volume fraction of 22.7% the hollow microspheres had porous surface 
structures.  
A development in our laboratory has been the creation of polymeric microcapsules 
which were prepared by a double emulsion (W/O/W) solvent evaporation process [20].  
In short, polymer and camphor were dissolved in methylene chloride and then a 4% 
ammonium carbonate was added to generate the (W/O) emulsion by probe sonication.  
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The (W/O/W) emulsion was created by pouring the (W/O) emulsion into a 5% poly vinyl 
alcohol (PVA) solution, which was then homogenized. 
 
2.3.3 History of the Current Polymeric Ultrasound Contrast Agent 
The focus of this thesis is the targeting of a novel polymeric ultrasound contrast 
agent originally developed by El-Sherif et al. [20]. The original contrast agent was made 
with 50:50 PLGA.  The microcapsules prepared in this manner are about 1.2 µm in size 
and during in vivo studies, the animals were not distressed after receiving up to 20 doses 
of the agent (in the range of 2 ml/kg of rabbit weight from a stock solution of 0.04g/ml).  
The capsules are also found to be echogenic in vitro.  The dose response was related to 
the frequency at which the capsules were insonated, producing an enhancement at 25oC 
of approximately 15, 25, 25 and 21 dB when insonated with 2.25, 5, 7.5 and 10MHz of 
ultrasound energy, respectively, for a dose of only 8μg of microcapsules/ml of buffer.  In 
vivo power Doppler imaging with the polymer contrast agent showed visual enhancement 
in comparison to the image taken without the agent.    
This contrast agent was further modified by J. Lathia [28]. It was determined that 
the monomer ratio of lactic acid (LA) to glycolic acid (GA) impacts the performance of 
the contrast agent.  In vitro, polymer blends of PLGA 75:25, 85:15, and PLA showed 
sufficient acoustic enhancement of up to 20dB and acoustic stability for 15 minutes at 
both 25°C and 37°C in comparison with PLGA 50:50 [29].  In vivo, all contrast agent 
blends showed sufficient acoustic enhancement of up to 20dB but the duration of contrast 
enhancement was dependent on the ratio of LA to GA since LA is more hydrophobic 
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than GA. The decision to proceed making the contrast agent using PLA in this thesis 
stemmed from these finding that PLA lasted the longest under insonation at 37°C. 
It was shown by K. Oum that the peptide-modified microbubbles could bind 
specifically to cells with integrin targets and that cellular binding was surface peptide 
density dependent with an optimal ratio of 0.5 Gly-Arg-Gly-Asp-Ser (GRGDS) peptide 
groups: total PLA carboxyl groups. GRGDS peptide modified microcapsules bound 
significantly (p<0.05) more to human breast cancer cells (MDA-MB-231) than 
unmodified PLA microcapsules in vitro [30]. 
The goals of this thesis are to enhance the targeting/treatment abilities of the 
above described polymeric ultrasound contrast agent by (1) functionalization of its 
surface both chemically and morphologically for cancer targeting, (2) bioconjugation of 
signal-inducing ligands and (3) targeting to novel receptors in ovarian cancer. 
 
2.4 Targeting Microbubbles for Molecular Imaging 
Many efforts are now being devoted to designing microbubbles that seek the molecular 
signature of diseased tissues, making them detectable by ultrasound [3, 5, 6]. Site-
targeted microbubbles are expected to provide higher sensitivity and specificity than 
standard blood pool ultrasound contrast agents, allowing earlier and safe assessment of 
pathology. Because microbubbles normally do not escape the circulation, binding to 
targets is essentially restricted to pathologies that express specific ligands within the 
vascular lumen, typically endothelial cells, leukocytes and thrombi. Targeting of 
activated endothelial cells may be particularly useful for signaling thrombi, areas of 
inflammation, atherosclerotic plaques and angiogenesis in solid tumors [31].  
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There are two strategies generally employed for targeting of microbubbles to 
pathology; passive and active targeting.  
 
2.4.1 Passive Targeting 
Passive, or non-specific targeting of contrast agent relies on size and shell 
characteristics to preferentially produce accumulation in regions of interest. Examples of 
passive targeting include illumination of the lymphatic system [32, 33], accumulation in 
the reticuloendothelial system [34-36] within phagocytotic cells at inflammation sites [2], 
and within tumors.  
Wisner et al. studied contrast agent enhancement in the lymphatic system, 
showing that subcutaneous injection of contrast media caused enhancement of 85% of 
sentinel lymph nodes in dogs [33]. Goldberg et al [32], examining whether lymphatic 
channels and sentinel lymph nodes with and without metastases can be detected after 
contrast agent injection in swine found it was not possible without contrast agent to 
determine lymph channels and sentinel nodes. After contrast agent injection, the lymph 
nodes became more echogenic as a result of passive contrast agent microbubble uptake. 
They found that lymphatic ultrasound with contrast agent administration can depict 
metastases within the sentinel lymph nodes.  
Passive Targeting is also illustrated by the prolonged visualization of liver and 
spleen injury, including tumor metastases. As certain microbubbles are slowed down in 
the circulation of the liver and spleen or are taken up by phagocytic cells that are part of 
the reticuloendothelial system (RES), there is highlighting of normal tissue of the organs, 
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but not tumors [35] RES accumulation also allowed evaluation of hemorrhage within the 
liver and spleen in dogs [36].  
Non-invasive assessment of inflammation is an important goal. Both albumin- 
and lipid-coated PFC microbubbles have been found to be retained in inflamed tissue [2]. 
Phagocytosed microbubbles remained acoustically active well after the blood pool 
concentrations had become negligible, providing a means of imaging inflammation and 
monitoring treatment [37]. Phagocytosed microbubbles are less easily destroyed by 
ultrasound than free microbubbles [37].  
 
2.4.2 Targeting via EPR effect 
It is a possibility that populations of the microbubbles may be able to extravasate 
into tissue from the large pores of leaky tumor vasculature. When aggregates of tumors 
achieve a diameter of 1-2mm they require neovasculature to supply nutrients. These 
vessels have an irregular, incomplete structure that includes pores. Yuan et al. measured 
the size of tumor vessel pores in LS174T human colon adenocarcinoma implanted in the 
dorsal skin chambers in immunodeficient mice [38].They showed that tumor vasculature 
pores could be as large as 0.4 microns in diameter. Researchers, using techniques like 
electron microscopy, have identified structural abnormalities in the endothelium of tumor 
vasculature [39, 40]. These abnormalities included cellular openings with a mean 
diameter of 1.7 microns (range, 0.3-4.7 microns) as well as transcellular holes with a 
mean diameter of 0.6 microns in mouse mammary carcinoma [41, 42]. 
If the microbubbles can escape the tumor vasculature, microbubble retention 
could be enhanced through the enhanced permeability and retention (EPR) effect. There 
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are many abnormal characteristics of solid tumors that influence EPR effect including 
active angiogenesis and high vessel density, unregulated production of vascular 
mediators that facilitate extravasation, defective vascular architectures, and impaired 
lymphatic clearance of macromolecules from interstitial tissue [42]. Evans blue dye 
revealed the presence of the EPR effect in rodent tumors after injection with Evans blue 
bound albumin (67kDa), producing a blue color in only tumor tissues [43]. The blue color 
was not seen in normal tissues, except those which surround the tumor or inflammation 
site. 
 
2.4.3 Active Targeting 
Active targeting refers to the attachment of bioactive adhesion ligands to cause 
the accumulation of contrast agents at a particular site. Ligands belong to various classes 
of molecules including monoclonal antibodies, polysaccharides and peptides that 
recognize disease antigens. Currently there is much research focused on active targeting 
of inflammation [2], thrombus [44, 45] and angiogenesis [6, 7, 28].  
Active targeting to the inflammation sites can be achieved using PFC 
microbubbles having antibodies to endothelial cell adhesion molecules that are expressed 
on the surface of endothelial cells activated during the inflammatory response [31]. Such 
molecules include intercellular adhesion molecule-1 (ICAM-1), P-selectin and certain 
integrins. F-butane microbubbles with anti-ICAM-1 monoclonal antibody covalently 
bound to a lipid component of the shell were reported to selectively attach to activated 
cultured endothelial cells in vitro, with minimal binding to non-activated cells [46]. In 
another approach, conjugation, via a biotin/avidin system, of antibodies against P-selectin 
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to F-butane/lipid microbubbles increased the retention of the microbubbles in inflamed 
tissue, allowing early detection of ischemia–reperfusion injury of the kidney in mice [47]. 
Detection of thrombus is another goal of active targeting. In vitro targeting and 
contrast enhancement of vascular thrombosis has been achieved with a lipid-coated PFC 
microbubble (MRX-408, ImaRx Pharmaceutical Corp., Tucson, AZ) having a peptide 
with an RGD sequence covalently attached via a PEG spacer to a lipid membrane 
component, dipalmitoylglycerol succinate [48]. The peptide binds selectively to the 
GPIIb/IIIa fibrinogen receptor that is expressed on the surface of activated platelets that 
attach to thrombi. In vivo detection of intravascular and intracardiac thrombus was 
demonstrated in animal model using such microbubble [49].  
A significant portion of this thesis is dedicated to targeting angiogenesis. 
Neovascularization in angiogenesis and arteriogenesis is important in wound healing, 
menses, tumor growth, invasion, and metastasis [17]. There is currently a lot of interest in 
influencing neovascularization for therapeutic reasons (especially in the case of anti-
angiogenesis drugs)  thereby creating a need for imaging of angiogenic markers in vivo 
for diagnostic purposes and measuring therapeutic effects [7, 50]. Targeted contrast 
enhanced ultrasound offers the possibility as well as providing information on 
microvascular perfusion and blood volume [17]. 
There are several studies targeting the integrin αvβ3, which is known to be 
required for angiogenesis [30, 51]. Targeting of αvβ3 has been accomplished with either 
monoclonal antibodies or peptides containing the RGD motif. Targeted ultrasound 
imaging with these microbubbles has been shown to detect neovascularization in matrigel 
plugs [7]. In a rat model of chronic ischemia targeting αvβ3 allowed the assessment of 
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baseline and growth factor induced angiogenesis [52]. Targeting of αvβ3 has also been 
shown to detect tumor induced angiogenesis [6]. 
 
2.5 Surface modification of microbubbles 
There are two general strategies for the attachment of the targeting ligand to the 
microbubble shell. In the first technique, the ligand is coupled to one of the shell-forming 
molecules (e.g. lipid) used as an anchor to retain the ligand prior to bubble fabrication. 
This approach works well for small organic molecule ligands, such as peptides, peptide 
mimetics, carbohydrates, hormones, and vitamins (such as biotin). Preparation of ligand-
lipid conjugates has been used for ligand attachment to microbubbles either directly or 
via a PEG spacer arm [49, 53]. The main advantage of this approach is the ability to 
perform the synthesis and product purification in the fully controlled conditions of an 
organic chemistry setup, ensuring high product yield and purity. This method is common 
for lipid shelled contrast agents, but not used for polymeric shelled contrast agents, , 
where harsh chemicals could destroy the ligand, or the ligand could become buried in the 
agent wall during synthesis.  
 When the bubble shell calls for covalent or noncovalent attachment of ligands to 
preformed microbubbles, as in polymeric contrast agents, a second general approach to 
ligand conjugation is used. This approach is most appropriate for the materials that are 
unstable in the conditions of continuous sonication, highspeed shear mixing, and 
resulting high temperatures, that are often associated with the preparation of 
microbubbles. Large protein molecules, such as antibodies or antibody fragments, are 
easily denatured in harsh conditions. To avoid denaturation of protein ligands, reactive 
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moieties that are stable enough to withstand bubble preparation conditions can be 
incorporated in the shell first (if reactive groups are not abundant naturally), 
functionalizing the surface, and then used for the attachment of the protein ligand to 
preformed bubbles.  
 
2.5.1 Ligand Attachment to Microbubbles 
The major methods of immobilizing a bioactive compound to a polymeric surface 
are adsorption via electrostatic interactions, ligand-receptor pairing (such as biotin-
avidin), and covalent attachment as depicted in figure 2.2.  
 
 
Figure 2.2: Mechanisms of immobilizing bioactive compounds to polymer surfaces [54].  
 
Non-covalent adsorption is sometimes desirable, for example in certain drug 
delivery applications. The biotin avidin bond is the strongest non-covalent bond [55]. It is 
used by many researchers because of the number of biotinylated reagents available. There 
are drawbacks to using biotin avidin chemistry because endogenous biotin (vitamin H) 
competes in vivo for binding sites and streptavidin is an immunogenic foreign protein.  
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Also its cationic nature results in rapid complexing with anionic sites in the renal 
glomerular basement membrane [54].   Covalent attachment has advantages over both 
these methods by providing the most stable bond between ligand and surface. A covalent 
attachment has been shown to extend the half-life of a biomolecule, prevent its 
metabolism (desirable for agents anti-cancer agents that may be toxic once metabolized), 
or allow for continued bioactivity when used within medical devices [56, 57]. Covalent 
linking is the primary method of ligand attachment used in this thesis. 
 
2.5.2 Functionalization of polymer surfaces 
Several surface modification techniques have been developed to tailor surfaces 
with specific functional groups that would then be available linkage to a ligand. These 
include wet chemical modification [58], silane monolayer modification [59], UV 
irradiation [60], and ionized gas treatment (plasma) [61], coating [62] and physical 
incorporation [11].  Coating and physical incorporation were chosen for further study in 
this thesis. Plasma and UV irradiation are also options for introduction of carboxylic acid 
to PLGA surfaces, however these methods provide modification of only the top 
nanometers of a polymer surface, which may not be optimal for functional group 
enhancement of round microbubble surfaces. 
 
2.5.3 Coating with carboxyl-carrying surfactants 
Protocols for making PLGA microbubbles by emulsion techniques commonly use 
surfactants to stabilize the emulsion. Most commonly, poly(vinyl alcohol) (PVA) is used 
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as the stabilizer. When the emulsion is formed, the hydrophobic backbone of PVA 
partitions into the organic phase, while the hydrophilic hydroxyl side chains partition into 
the aqueous phase. Upon removal of the organic solvent, the surfactant is retained and the 
hydrophilic side chains remain exposed on the surface of the newly formed microspheres. 
This surface layer is suggested to be quite durable, remaining present even after repeated 
washing of the microbubbles, suggesting that the surfactant molecules are incorporated 
directly into the microbubble surface during fabrication [62]. Other functional groups 
aside from hydroxyls, however, would be more suitable for many surface modification 
chemistries.  
Keegan et al. demonstrated an alternate stabilizer, poly(ethylene-alt-maleic acid) 
(PEMA) to produce microbubbles that allow the binding of ligands to the microbubble 
surface by carbodiimide chemistry [63]. The carboxylic acid side chains of PEMA, 
present at the microbubble surface, can be linked to primary amine groups of the 
desired ligand, forming stable amide bonds. They found that the capacity for ligand 
binding of PLGA/PEMA microspheres is substantially improved over those made of 
PLGA with acid end groups and PVA as stabilizer [63].  
Keegan et al. reasoned that two features lead to the high density of functional 
carboxyl groups at the microbubbles surface. First, the carboxyl side chains are repeated 
along the entire length of the stabilizer molecule, providing a high density of functional 
groups as compared to PLGA molecules that are functionalized only at the ends of the 
polymer chain, and secondly the stabilizer molecules partition at the interface of the 
organic and aqueous phases of the emulsion that is formed during microbubble 
production. The surfaces of the microbubbles form at this interface during the solvent 
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evaporation step, meaning that the functional groups are localized at the microbubble 
surface and not buried within the core (they evaluated solid PLGA microspheres) [62].  
In a subsequent study the researchers demonstrated that PLGA/PEMA 
microspheres could be conjugated to a variety of protein ligands. They found that these 
targeted microspheres could be retained in agarose columns and showed adhesion to cell 
surface receptors in Caco-2 cells [63]. 
 
2.5.4 Physical incorporation of Lipid-PEG-Biotin conjugates  
The primary strategy of targeting contrast agents to specific sites involves 
modifying the surface of the contrast agent with ligands that home-in to specific sites of 
the vasculature.  These ligands can either be attached covalently or by use of the biotin-
avidin interaction as described previously. Another approach has been to use physical 
incorporation of lipid-ligand conjugates: this approach has been primarily explored in the 
formation of lipid-based contrast agents, and more recently with solid polymer 
microspheres [11], but has not yet been extended to polymer-based contrast agents. The 
physical incorporation method may overcome the difficulties of other methods of 
functionalization that lead to limited density of functional groups and decreased targeting 
effects due to desorption of the ligand during particle erosion. 
In the work of Fahmy et al., avidin–palmitate conjugates were incorporated on the 
surface of solid PLGA particles  [11]. The conjugate naturally positioned itself at the 
material surface: the palmitic acid preferentially partitioned into the hydrophobic PLGA 
matrix, whereas the hydrophilic avidin head group was display in the hydrophilic external 
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environment, facilitating the attachment of biotinylated ligands to the surface of their 
solid microspheres.   
In this thesis a similar strategy is employed, at the suggestion of Dr. Joyce Wong 
of Boston University, with the incorporation of 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Biotinyl(Polyethylene Glycol)2000 (DSPE-PEG-biotin) into 
the shell. Using this method, biotin-avidin chemistry can be employed to conjugate 
bioactive ligands. Additionally, there are benefits to having PEG on microbubbles. Using 
a hydrophilic spacer molecule such as PEG may shield a compound from denaturation 
and improve bioactivity [64].  
 
2.5.5 Morphological surface modification  
Bubble morphology may be another factor in addition to chemical modification of 
bubbles enabling retention. A recent study by Rychak et al. featured “wrinkled” P-
selectin targeted microbubbles created by application of a positive hydrostatic pressure of 
750 mm Hg to a dispersion of spherical microbubbles, resulting in the formation of 
outward-projected structures on the surface [8]. They hypothesized enhanced 
microbubble capture could be achieved with the wrinkled bubbles because microvilli 
bearing clustered adhesion molecules [65] are responsible for efficient capture of 
leukocytes to inflamed endothelium in vivo[66]. The outward-projected structures on the 
surface of the wrinkled microbubbles resemble neutrophil microvilli.  They report that 
microbubble bound by a single antibody molecule located at the tip of a 0.5 μm wrinkle 
experiences a 55% lower bond force than a spherical particle in which the ligand is flush 
with the microbubble surface resulting in the stabilization of a captured particle [8]. 
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They found that wrinkled microbubbles form sustained adhesion events with 
higher efficiency than spherical microbubbles in vitro. The adhesion of P-selectin 
targeted microbubbles was examined in a flow chamber, and the wrinkled microbubbles 
exhibited significantly (p <0.05) greater sustained adhesion than spherical microbubbles 
[8]. In addition, they found that wrinkled microbubbles exhibited enhanced adhesion in 
the inflamed mouse cremaster [8], in wild type mice (10 venules) approximately 14.5 ± 
1.5 wrinkled microbubbles were retained versus 6 ± 1 retained for spherical 
microbubbles .  A similar concept using rough surfaced PLGA microbubbles having 
outward projected structures is developed and evaluated in this thesis. 
 
2.5.6 Immobilization of bioactive compounds 
If a surface is functionalized or has functional groups naturally, it can be 
covalently decorated with targeting ligands. Common functional groups in 
bioconjugation chemistry include thiols, aldehydes, carboxylic acids, hydroxyls, and 
primary amines. The development of numerous cross linking agents, such as 1-Ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) and (N-[ß-Maleimidopropionic acid] 
hydrazide) (BMPH), has expanded the array of usable conjugation chemistries. These 
chemistries are outlined in detail in a definitive text, Bioconjugate Techniques, by 
Hermanson [67]. Like the bioactive ligands themselves, crosslinkers have different 
optimum pH values, temperatures and solubilities and should be selected based on the 
conditions needed for the polymer/ligand conjugation. Crosslinkers can link the ligand 
directly to the surface (zero-length crosslinkers such as EDC) or they can introduce a 
spacer arm of several angstroms (such as PEG and BMPH) [67]. 
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2.5.7 Surface Characterization 
The type of analytical tools used for characterizing surface modified polymers 
depends on the anticipated nature of the modification and the specificity required.  
Current non-spectral methods of characterization include dye assays using 
colormetric dyes (with a standard curve) that change color in the presence of a specific 
chemical group, protein assays such as the Bradford or Bicichonic acid (BCA) assay 
which generate or change color when complexed with protein, assays for biological 
activity such as antigen binding, flow cytometry or cellular attachment analysis, and zeta 
potential testing which detects changes in charge on the surface of the polymer [54]. The 
research in this thesis utilizes protein assays, various biological assays and zeta potential 
testing for characterization of our modified polymers. 
 Current spectroscopic and microscopic analyses include X-ray photoelectron 
microscopy (XPS) which determines the atomic composition of a surfaces top several 
nanometers, time-of-flight secondary ion mass spectrometry (ToF-SIMS) to determine 
the type and quantity of ionizable chemical groups on a surfaces top nanometer, Fourier 
transform infrared spectroscopy (FTIR) which determines the chemical functionalities 
present in a sample using infrared radiation, and atomic force microscopy (AFM) and 
scanning electron microscopy (SEM) for surface morphology measurements. In this 
research FTIR and AFM characterization methods were applied, however SEM was 
found to be most useful for microscopic analysis of the microbubbles [54]. 
 
 27
2.5.8 Challenges and Considerations of ligand conjugation 
It is known that the activity of a bioactive ligand may change after immobilization 
onto a surface, most likely due to the differences between the bulk solution and surface 
microenvironmental conditions or alteration of the active site by distortion due to the 
chemical linkages. For example, enzymes linked to polycationic surfaces had their pH 
shifted to a more acidic value [68], and those on polyanionic surface shifted to a more 
alkaline value [69]. Also depending on the conjugation chemistry chosen, linking a 
bioactive ligand to a solid surface may introduce steric constraints.  It is important to 
consider that ligand behaviors observed in measured bulk solution may not be 
representative of those occurring bound to the polymer surface. 
 When looking at the bioactivity of ligand:polymer conjugates its important to 
have the appropriate controls. Since surface functionalization is usually a multistep 
process, the surface charge and hydophilicity can change. Its not only important to 
compare the bioactivity of the ligand:polymer conjugate with the unmodified polymer, 
but also to compare the bioactivity of the surface modified polymer to which the ligand 
has not yet been attached; that is, adding a control of microbubbles that have gone 
through the functionalization or conjugation process without ligand addition. By 
including this process it can be identified whether a change in bioactivity in the 
microbubbles is due to the ligand or simply a change in microbubble surface chemistry. 
Also, in some applications it may be critical that the bond between ligand and polymer be 
covalent [54]. This can be confirmed by comparing samples made with and without the 
chemical crosslinker, ruling out simple adsorption. 
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 It is important to optimize rather than just maximize the density of surface 
immobilized ligands. An example by Wheatley et al. [70] demonstrated that there is an 
optimal density of RGD ligands immobilized on the surface of polymer microbubbles for 
cellular attachment.  
 Lastly, a benefit of working with surface based chemistries is the relative ease of 
purification with processes such as wash steps to adequately rid the surface of unwanted 
physically adsorbed or electrostatically attached ligands. Wash steps must be included in 
conjugation procedures; samples made without wash steps may produce clouded results.  
 
 
2.6 Cancer 
Cancer is a disease characterized by the formation of abnormal tissue (neoplasm), 
and generally is a change in the way cells proliferate and differentiate. Tumors require 
the development of new blood vessels, known as angiogenesis, to provide the necessary 
nutrients for their growth.  
 Surgery, radiation therapy and chemotherapy are the current treatment options for 
cancer [71]. Local treatments, radiation therapy and surgery are used when the tumor has 
not metastasized. Once it is metastasized, chemotherapy, a systemic treatment, is also 
required. Anti-cancer agents affect different parts of the cell cycle and have side effects. 
Systemic treatment can affect all tissues, both normal and malignant [71].  
Ultrasound contrast agents have been used to image and diagnose cancer, recently 
Forsberg et al. compared various modes of ultrasound with and without contrast agent to 
mammography for the diagnosis of breast cancer in 14 women. They suggested 
subharmonic imaging (which utilizes contrast agent) may increase the ability to diagnose 
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breast cancer [72]. The same group has also found that tumor neovascularity measured 
with contrast enhanced ultrasound (using Optison (GE Healthcare, Princeton, NJ) and 
Sonazoid (GE Healthcare, Princeton, NJ)) is significantly correlated with histological 
staining of vascular endothelial growth factor (VEGF), endothelial cells (CD31), and 
cyclooxygenase-2 (COX-2)  in mice with melanoma tumors [50].  
 
2.6.1 Angiogenesis 
Angiogenesis is the growth of new blood vessels and plays a key role in  fetal 
development, wound repair, menses, inflammation, rheumatoid arthritis, and cancer [4]. 
There has been much interest in developing therapeutic agents that inhibit angiogenesis. 
The detection, diagnosis, and monitoring of angiogenesis is also an application of 
ultrasound [50].  
Angiogenesis is characterized by the invasion, migration, and proliferation of 
smooth muscle and endothelial cells [4]. Angiogenesis is essential for the growth of 
tumors past a few millimeters; if a tumor does not have vasculature to feed its growth, it 
will not develop into a larger tumor. If the tumor does begin to have vasculature develop 
around it, the growth and metastatic potential of the tumor increases [73]. 
 The development of vasculature is initiated by the tumor, which releases factors 
that increase blood vessel growth and development.  Next, the surrounding parental 
vessels vasodilate and the basement membrane of the vessels begins to degrade via 
proteolytic enzymes.  Endothelial cells begin to migrate into the extracellular space and 
proliferate to form a leading edge.  The endothelial cells form tubules with lumen and 
begin to synthesize basement membrane.  Finally, the tubules anastamose and recruit 
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smooth muscle cells and pericytes to complete the vessel structure near or surrounding 
the tumor [73].  Due to rapid formation of new blood vessels into tumors, the new 
vascular is irregular and leaky. It is thought that the porous nature of the new vessels 
might aid metastasis, and also lead to the collection of fibrin in the extracellular matrix to 
promote angiogenesis [73]. 
 
2.6.2 Integrins  
Integrins are transmembrane receptor proteins, and are the main way cells bind 
and respond to the extracellular matrix. Integrins also influence many aspects of cell 
behavior such as morphology, cell adhesion, cell migration, and cellular proliferation and 
differentiation [74]. Many cell-signaling cascades, such as that for continued proliferation 
or death of a cell, begin with a ligand binding to integrin receptors.  Thus, cell surface 
integrins represent a good target to prevent signaling cascades.  As a tumor grows and 
develops it requires vasculature and it is theorized that chemotherapeutic agents bound to 
the growth factor receptors could result in localized cytotoxic effects [12].  Therefore, if 
these receptors can be targeted and blocked, angiogenesis may be effected and thus, the 
growth of the developing tumor can be reduced or even stopped.  
 The αvβ3 integrin is implicated in many pathological processes, such as 
osteoporosis, misregulated angiogenesis (e.g., rheumatoid arthritis or retinopathy) as well 
as tumor growth, and tumor metastasis [75]. This receptor is highly expressed on many 
tumor cells such as neuroblastomas, carcinomas of the lung, the breast, the prostate and 
the bladder [75]. It has been shown that the αvβ3 integrin is important during tumor-
induced angiogenesis [4]. The phenomenon consists of the involved endothelial cells 
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expressing αvβ3 to adhere on the extracellular matrix during migration toward the tumor. 
It has been shown that the inhibition of the αvβ3 integrin with monoclonal antibodies or 
peptidic antagonists results in a drastic reduction of neovascularization around the tumor, 
leading to the starvation of the tumor [76].  
The integrin αvβ3 binds to a wide variety of extracellular matrix proteins [51]. A 
common receptor recognition motif of these matrix proteins is the peptide sequence Arg-
Gly-Asp (RGD). 
 
2.6.3 RGD 
The RGD sequence is the most often employed peptide sequence for stimulated 
cell adhesion on synthetic surfaces as well as surface targeting [77]. The tripeptide motif 
RGD was identified 18 years ago by Pierschbacher and Rouslahti as a minimal essential 
cell adhesion peptide sequence in fibronectin [78]. Since then, cell adhesive RGD sites 
were identified in many other ECM proteins, including vitronectin, fibrinogen, von 
Willebrand factor, collagen, laminin, osteopontin, tenascin and bone sialoprotein [78]. 
The RGD sequence is a non-specific binding sequence, however it can be made specific 
by the addition of extra amino acids.  This binding specificity is dictated by many things 
including the cyclization of the peptide sequences and the conformation of disulfide 
bonds.  About half of the 24 integrins have been shown to bind to ECM molecules in a 
RGD dependent manner [78]. In cancer biology, the main receptors of interest for 
angiogenesis targeting are cell surface integrins αvβ3 and αvβ5. 
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A lock and key relationship has been identified between integrins overactive in 
angiogenesis, αvβ3 and αvβ5, and the RGD peptide.  Consequently, there have been 
attempts made to target angiogenesis using the RGD peptide sequence [77].   
 
2.7 Apoptosis  
Apoptosis, also known as programmed cell death, has critical roles in the 
development, homeostasis maintenance and host defense in multicellular organisms. It is 
characterized by DNA fragmentation, chromatin condensation, membrane blebbing and 
cell shrinkage [79]. Apoptosis occurs through extrinsic and intrinsic apoptotic pathways. 
The final step involved in each pathway is a caspase cascade, which cleaves regulatory 
and structural molecules, leading to cell death.  
The extrinsic pathway of apoptosis is also known as the cytoplasmic or death 
receptor (DR) pathway. Extracellular agents such as tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), Fas ligand  (FasL) and Tumor Necrosis Factor (TNF) 
induce the extrinsic pathway through the activation of specific DRs distributed on the 
plasma membrane. Specific DRs become activated by their specific ligands and as a 
result they form dimer/trimer complexes. Within seconds the activated DRs recruit 
adaptor molecules, which further transmit the death signals to DISC, where the 2 adaptor 
proteins FADD and TNF receptor-associated death domain have been shown to recruit 
caspase-8 or 10 to activate the extrinsic apoptotic pathway [79]. The intrinsic mechanism 
of apoptosis acts by perturbation of the mitochondrial membrane, and relies on the 
release of key apoptogenic factors such as cytochrome c and apoptosis-inducing factor 
[80]. These intrinsic and extrinsic pathways are depicted in figure 2.3 taken from [80]. 
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Figure 2.3: Apoptosis: the ‘extrinsic’ and ‘intrinsic’ pathways to caspase activation. Two major apoptotic 
pathways are illustrated: one activated via death receptor activation (‘extrinsic’) and the other by stress-
inducing stimuli (‘intrinsic’). Triggering of cell surface death receptors of the tumour necrosis factor (TNF) 
receptor superfamily, including CD95 and TNF-related apoptosis-inducing ligand (TRAIL)-R1/-R2, results 
in rapid activation of the initiator caspase 8 after its recruitment to a trimerized receptor-ligand complex 
(DISC) through the adaptor molecule Fas-associated death domain protein (FADD). In the intrinsic 
pathway, stress-induced apoptosis results in perturbation of mitochondria and the ensuing release of 
proteins, such as cytochrome c, from the inter-mitochondrial membrane space. The release of cytochrome 
c, from mitochondria is regulated in part by Bcl2 family members,with anti-apoptotic (Bcl2/ Bcl-XL/Mcl1) 
and proapoptotic (Bax, Bak and tBid) members inhibiting or promoting the release, respectively. Once 
released, cytochrome c binds to apoptotic protease-activating factor 1 (Apaf1), which results in formation 
of the Apaf1–caspase 9 apoptosome complex and activation of the initiator caspase 9. The activated 
initiator caspases 8 and 9 then activate the effector caspases 3, 6 and 7, which are responsible for the  
cleavage of important cellular substrates resulting in the biochemical and morphological changes associated 
with the apoptotic phenotype [80]. 
 
 
There have been several studies investigating the effect of ultrasound and 
ultrasound contrast agents on cellular apoptosis [81, 82].  
Feril et al. [81] determined the effects of ultrasound contrast agents on ultrasound 
induced apoptosis and cell lysis in human lymphoma U937 cells. Cells in suspension 
 34
were exposed to 1 MHz continuous waves ultrasound for 1 min at various intensities with 
or without commercial contrast agents. Apoptosis was detected by flow cytometry. They 
determined  Optison (GE Healthcare, Princeton, NJ) was effective in augmenting the 
ultrasound induced cell death, indicating that cavitation plays a role in the augmented 
effects. A similar study by Honda et al. [82] evaluating the effect of free radial formation 
during cavitation, found that ultrasound induced apoptosis of U937 cells, which is 
mitochondria-caspase dependent, was linked to cavitation. When the cells were insonated 
in the presence of Levovist; synergistic enhancement of secondary necrosis was observed 
at concentrations of more than 20 mg/mL [82]. Their results suggest that contrast agents; 
acting as cavitation nuclei, can enhance ultrasound-induced apoptosis/secondary necrosis 
due to an increase in cell membrane damage.  
These findings support the concept that ultrasound contrast agents have the 
potential to be adjuncts in cancer therapy with, in particular those therapies which rely on 
apoptosis induction such as the TRAIL therapy. 
 
2.7.1 TRAIL and TRAIL receptors 
TRAIL is a ligand, which can induce apoptosis in tumor cells after binding to 
death inducing receptors TRAIL-R1 and R2, also known as DR4 and DR5.  Activation of 
DR4 and DR5 lead to the induction of death inducing signals from the plasma membrane 
to the cytoplasm It has been shown that TRAIL induces  cell death in various cancer cells 
[83] such as breast cancer [84] and glioma [85]. TRAIL has a sequence homology similar 
to that of TNF and FasL [86]. The advantage of TRAIL over TNF and FasL is the fact 
that it is non toxic to normal cells [86]. The disadvantage of TRAIL is that it has no 
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specificity to tumor tissue alone. Binding to normal tissues, which also have TRAIL 
receptors results in a lower availability of TRAIL to tumor cells [87]. 
Ashkenazi et al. outlines why TRAIL is non-toxic to normal tissues, though 
TRAIL receptors are present [88]. Protection of normal tissues is based on a set of decoy 
receptors (DcRs), which compete with DR4 and DR5 for binding to TRAIL. DcR1 is a 
cell surface protein resembling DR4 and DR5, but lacks a cytoplasmic tail. DcR2 is 
another receptor that resembles DR4 and DR5, but as a truncated cytoplasmic death 
domain.  Both DcR1 and DcR2 function as decoys that prevent TRAIL from binding to 
its death receptors. DR4 and DR5 are expressed in normal tissue and in many types of 
tumor cells, whereas DcR1 and DcR2 are expressed frequently in normal cells but 
infrequently in tumor cells [88]. This differential expression of death and decoy receptors 
might enable TRAIL to induce apoptosis in tumors while sparing normal cells. 
The unique capacity of TRAIL has been exploited by pharmaceutical companies 
and various versions of TRAIL are currently being tested in clinical studies. Soluble 
TRAIL has entered phase I clinical trials (Genentech in collaboration with 
Amgen/Immunex). Also being tested are anti-DR4 and anti-DR5 monoclonal antibodies. 
Mapatumumab (Human Genome Sciences), an anti-human-DR4 antibody is currently 
enrolled in three phase II clinical trials, and at least five DR5-specific agonistic 
antibodies, including Lexatumumab are in late preclinical or in early clinical studies [79].  
 
2.7.2 TRAIL and Velcade Induced Apoptosis 
 
The ubiquitin-proteasome system is main degradation pathway for proteins involved 
in the regulation of cell survival, proliferation, apoptosis, and other critical cellular 
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functions [89]. It has recently been shown that the proteasome inhibitor Velcade, also 
known as PS-341 or Bortezomib, (Millenium Pharmaceuticals, Cambridge, MA) can 
interfere with tumor cell regulation, blocking proliferation and causing cell death [90-92]. 
Velcade induces apoptosis via an intrinsic cell death pathway, which relies on the 
release of proapoptotic proteins from mitochondria such as a second mitochondria-
derived activator of caspases/direct inhibitor of apoptosis binding protein with low pI 
(SMAC/Diablo) and cytochrome c [89]. TRAIL induces apoptosis via an extrinsic 
pathway through interaction with death receptors/ direct activation of caspases [89]. The 
intrinsic and extrinsic apoptosis signaling pathways communicate with each other. 
Caspase-8 has been shown to cleave the proapoptotic Bcl-2 family member Bid. The 
cleavage of Bid by caspase-8 and the translocation of truncated Bid to the mitochondria 
to promote cytochrome c release provides a plausible mechanistic link between the 
extrinsic and intrinsic pathways [93]. This apparently amplifies the apoptotic signal 
following death receptor activation [94]. Conversely, activators of the intrinsic pathway 
can sensitize cells to extrinsic death ligands.  
 Recently, there have been many studies confirming a synergistic apoptotic effect 
of treating cancer cells with a combination of Velcade and TRAIL. It has been 
demonstrated in human pancreatic [91], human bladder [92], human prostate [92], renal 
[90], colon [90] and breast [90] cancer cell lines. A recent study by Conticello et al. [95] 
showed that the cytotoxic effect of Velcade in thyroid carcinoma cells was potentiated 
through combination treatment with TRAIL, predictably allowing the clinical usage of 
lower doses of both compounds. They also showed that because both intrinsic and 
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extrinsic cell death pathways are activated with TRAIL/Velcade combination treatment, 
mechanisms of death resistance could be overcome [95]. 
 
 
2.8 Ovarian Cancer  
Ovarian cancer (OC) is the second most common and most lethal gynecologic 
malignancy in the USA. Epithelial OC comprises the majority of malignant ovarian 
tumors [96].  Over 70% of women with OC are diagnosed with advanced stage disease, 
with a 5 year survival rate 30%. This 5 year survival rate is 90% when diagnosed early 
(disease confined to the ovaries), but only 25% of cases are found in this early stage. 
Incidence rates remain high and mortality rates are virtually unchanged over the last 30 
years [96]. Clinicians screen for OC by measuring CA-125 levels in the blood (elevated 
in most women with OC) in combination with transvaginal ultrasound.  
 
2.8.1 CA-125 in as a Target Ovarian Cancer 
CA-125 is a biomarker for ovarian cancer. The discovery of OC-125, and 
antibody that recognizes CA-125 was discovered by Bast and his colleagues in 1981 [97]. 
CA-125 is expressed as a membrane-bound protein at the surface of cells or is released in 
soluble form into bodily fluids [96]. 
Since OC occurs in the peritoneal cavity, the regional administration of therapy is 
possible. Therapies for epithelial OC are being developed and are in clinical trials. 
Oregovomab (Unither Pharmaceuticals, MA) is an immunotherapeutic agent for patients 
with ovarian adenocarcinomas expressing CA-125. Oregovomab operates with a unique 
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mechanism, the antibody forms a complex with serum soluble CA-125 and this complex 
binds to antigen presenting cells such as macrophages and dendritic cells. The complex 
triggers induction of CA-125 specific immune responses. Oregovomab was shown to 
increase the survival time of epithelial OC patients [98].  
Targeted therapies with anti-CA-125 antibodies conjugated to anti-cancer drugs 
are currently under study in animal models. A recent publication compares the toxicity 
and efficacy of two such antibodies and reported efficacy in vitro and in vivo [99]. Efforts 
have been undertaken to develop anti-CA-125 antibodies specific for the cell-associated 
form of the antigen, which is of particular interest for targeted therapy [100]. 
CA-125 is a biomarker with a broad range of utility; risk, early detection, 
diagnosis, prognosis, monitoring and therapy. It also represents an attractive therapeutic 
target and therefore is studied as a target in this thesis. 
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3. MATERIALS AND METHODS 
 
 
3.1 Materials  
3.1.1 Polymers  
Poly (D,L-lactic-co-glycolic acid), Medisorb 50:50 3.5A lot # 0098-441, 
Medisorb 50:50 5A lot # 01-112-66, Medisorb 50:50 6A lot # 01-141-108, and Medisorb 
100:0 6E lot # W2297-587) was purchased from Lakeshore Biomaterials, Birmingham, 
AL.   The polymers designated E were endcapped with lauryl ester and those designated 
A were uncapped.  The molecular weights and inherent viscosities of the polymers were 
as reported in Table 3.1. 
 
 
Table 3.1: Polymer formulation molecular weight and inherent viscosity 
 
Polymer formulation 
(lactic acid: glycolic 
acid) + designation 
Molecular weight  
(kDa) 
Inherent Viscosity 
(dL/g) 
50:50_3.5A 51 0.4 
50:50_5A 76 0.51 
50:50_6A 91 0.6 
100:0_6E 83 0.55 
 
3.1.2 Targeting Ligands and Chemical Crosslinkers  
The GRGDS (Gly-Arg-Gly-Asp-Ser) peptide sequence (Mw 490.5Da), human 
recombinant Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) (cat.# 
T9701), EDC (1-Ethyl-3-13-Dimethylamino-Propyl) carbodiimide,  and NHS (N-
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hydroxysuccinimide) was purchased from Sigma-Aldrich Chemical Co., St. Louis, MO. 
Murine anti-CA-125 monoclonal antibody was purchased from QED Bioscience, San 
Diego, CA (cat. #3330). 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-
[Biotinyl(Polyethylene Glycol)2000 (DSPE-PEG-biotin) was purchased from Avanti 
Polar Lipids, Alabaster, AL (cat. # 880129). (N-[ß-Maleimidopropionic acid] hydrazide) 
(BMPH) was purchased from Pierce, Rockford, IL. Scrambled peptide used as a control, 
GRDGS (Gly-Arg-Asp-Gly-Ser) was from Biosynthesis Inc., Lewisville, TX. 
 
3.1.3 Antibody Fragmentation and Detection Materials 
 Easy-Titer antibody detection kit was purchased from Pierce, Rockford, IL. 
Antibody fragmentation kits were purchased from Fisher Scientific, Springfield, NC. 
Alexa Fluor® 488 carboxylic acid, succinimidyl ester was purchased from Invitrogen, 
Carlsbad, California.  Human Ovarian Cancer Antigen CA-125 was purchased from 
Meridian Life Science, Saco, ME (lot#1D09208).  
 
3.1.4 Cell Lines and Cell Culture Materials 
Human breast adenocarcinoma cells (MDA-MB-231) and human ovarian cancer 
cells (NIH:OVCAR-3)  and human melanoma cells (A2058) were purchased from 
ATCC, Manassas, VA. Bovine insulin and penicillin/streptomycin antibiotic were 
purchased from Sigma Chemical Co., St. Louis, MO. RPMI-1640 medium (containing 2 
mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L glucose, and 1500 
mg/L sodium bicarbonate) and Eagle's Minimum Essential Medium (EMEM) (containing 
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Earles Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM 
sodium pyruvate, and 1500 mg/L sodium bicarbonate) were purchased from ATCC 
Manassas, VA. 0.25% Trypsin EDTA and fetal bovine serum (FBS) were purchased from 
Fisher Scientific, Springfield, NJ.  
 
3.1.5 Fluorescent Probes and Cellular Assay Materials 
Vybrant Apoptosis Assay Kit #2 containing alexafluor 488 -annexin V and propidium 
iodide, Hoechst blue 33342 nucleic acid stain, a cationic green dye 3,3’-
diethyleneoxacarbocyanine iodide DiO(C2)3 , and 5-aminoacetamido fluorescein were 
purchased from Invitrogen, Carlsbad, CA. Guava Nexin Reagent Kit for apoptosis 
detection was purchased from Guava Technologies, Hayward, CA. Nile Red was 
purchased from Sigma, St. Louis, MO. 
 
3.1.6 Other Chemicals  
Poly (vinyl alcohol) (PVA), 88% mole hydrolyzed, with a Mw of 25kDa and Poly 
(ethylene maleic anhydride) (PEMA), with a Mw of 100kDa was purchased from 
Polysciences, Inc., Warrington, PA. PVA, 88% mole hydrolyzed, with a Mw of 133kDa, 
(2-[N-morpholino]ethanesulfonic acid) sodium salt (MES), thioglycolic acid, laboratory 
grade (1R)-(+)-camphor and laboratory grade ammonium carbamate was purchased from 
Sigma-Aldrich Chemical Co., St. Louis, MO.  Pharmaceutical grade ammonium 
carbonate was purchased from J.T. Baker, Phillipsburg, NJ. Sodium chloride, methlyene 
chloride, acetone, hexane, methanol, and isopropyl alcohol were all reagent grade and 
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purchased from Fisher Scientific, Springfield, NJ.  Velcade (PS-341) was graciously 
supplied by Millenium Pharmaceuticals Cambridge, MA. 
 
3.2 Contrast Agent Preparation and Characterization 
3.2.1 Microcapsule Fabrication 
Polymer microbubbles were prepared by a modified double emulsion process 
[70].  A detailed description of the procedure is given in Appendix A.  Microbubbles 
were prepared by adapting the double emulsion (W/O)/W solvent evaporation process 
using ammonium carbamate as a sublimable core.  PLGA or PLA (0.5 g) was  dissolved 
in 10 ml of methylene chloride. To generate the first (W/O) emulsion, 1.0 ml of 4% 
ammonium carbonate solution was added to the polymer solution and probe sonicated at 
115 Watts for 30 seconds.  The (W/O) emulsion was then poured into a 5% PVA (at 4oC) 
solution and homogenized for 5 minutes at 9,500 rpm.  The double emulsion (W/O)/W 
was then poured into a 2% isopropyl alcohol solution and stirred for 1 hour with a 
magnetic stirrer on a magnetic stir plate at a speed fast enough to create a vortex that 
spanned the entire beaker diameter. The microcapsules were collected by centrifugation 
for 5 minutes at 5000 times g force, washed three times with hexane, then once with 
deionized water and lyophilized, using a Virtis Benchtop freeze dryer, to remove the 
ammounium carbamate core. 
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3.2.2 Variations to fabrication procedure 
3.2.2.1 Microbubbles with PEMA surfactant 
Poly(ethylene-alt-maleic acid) was synthesized via an acid/base ring-opening of poly 
(ethylene maleic anhydride) (PEMA). Poly (ethylene maleic anhydride) was slowly 
added to a 1M NaOH solution, stirred overnight, corrected to pH 6.5 with HCl and 
filtered. 1, 3, 5 and 7% w/v solutions of PEMA were created. Blends of PEMA:PVA 
were created by blending the two surfactants at PEMA:PVA at weight ratios of 0:100, 
25:75, 50:50, 75:25 and 100:0, using 5% w/v PEMA and PVA. During the second 
emulsion of the fabrication process the 50ml of PVA surfactant was replaced with 50ml 
of a PEMA solution or 50ml of a blend of PEMA:PVA. The fabrication process then 
proceeded as described in Appendix A.  
 
3.2.2.2 Physical incorporation of DSPE-PEG-Biotin 
For microbubbles with physically incorporated 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Biotinyl(Polyethylene Glycol)2000] (DSPE-PEG-Biotin),  
DSPE-PEG-Biotin was added the mixture of PLA and organic solvent, prior to the first 
emulsion, in a 1:100 ratio of lipid:polymer. The DSPE-PEG-Biotin was dispensed into a 
50ml beaker with a glass syringe, the solution was dried under argon gas and desiccated 
under vacuum for 3 hours. With the DSPE-PEG-Biotin dried to the glass beaker, 10ml of 
methylene chloride solvent was added into the beaker. Next polymer was added and the 
fabrication process proceeded as described in Appendix A. 
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3.2.2.3 Nile Red Preparations 
To physically incorporate the fluorescent probe Nile Red into the shells of the 
microbubbles, Nile Red was added at a 1:100 w/w ratio to the polymer in the organic 
phase prior to the first emulsion. This procedure was adapted from [101].  The fabrication 
process proceeded as described in Appendix A.  
 
3.2.2.4 Shape studies 
For microbubble studies examining the effect of surface morphology, parameters 
were varied in the fabrication process in order to create a range of microbubbles with 
varied morphology but made from the same class of polymer. The parameters altered 
included type of polymer (free acid or end capped), water to oil ratio in first emulsion 
(1:10 and 1:20), surfactant molecular weight, and amounts of porogens. Other parameters 
included stirplate speed (800rpm to 400prm) used during solvent evaporation.  
Fabrication began with dissolving 0.5g of 50:50 3.5A, 50:50 5A or 50:50 6A 
PLGA 50:50 polymer in either 10ml or 20ml of methylene chloride solvent. To this 
solution either 25mg or 50mg of camphor was added. Next, 1ml of a 20mg/ml or 
40mg/ml solution of ammonium carbonate was added. The solution was sonicated for 
30seconds in an ice bath in pulse mode 3seconds on, 1 second off. This first emulsion 
was then poured into a 5% w/v surfactant solution made with either 133kDa Mw PVA or 
25kDa Mw PVA and homogenized at 10,500 rpm for 5 minutes. 100ml of 2% IPA 
solution was then added and the solution stirred on a stirplate at a speed of 400rpm for 
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1.5 hours. Microbubbles were then collected via centrifugation, washed with hexane 3x, 
frozen and lyophilized for 48 hours.  Details of the microbubble fabrication procedure are 
described in Appendix A. 
 
 
3.3 Conjugation methods 
3.3.1 Peptide Conjugation via Carbodiimide Linkage 
Freeze-dried microbubbles (50mg) were suspended in 2ml of buffer (0.1M MES, 
pH 5.2) in a centrifuge tube. To this 0.8mg of EDC (2mM) and 2.2mg of NHS (5mM) 
was added. The solutions were shaken on an end-over-end shaker for 30 mins for EDC 
activation of microbubble surfaces. The solutions were then centrifuged and washed 3 
times to remove excess EDC. GRGDS peptide was then added at a 0.5:1 molar ratio of 
peptide to total polymer carboxyl groups. Samples were shaken end-over-end for 3 hours, 
centrifuged and washed 3 times with buffer (PBS, pH 7.0), frozen and lyophilized for 48 
hours. Detailed descriptions of the procedures are given in Appendix B, part A.  The 
general reaction is as follows, figure 3.1:  
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Figure 3.1: Carbodiimide linkage. EDC reacts with a carboxyl group on a PLA microbubble (1), forming 
an amine-reactive O-acylisourea intermediate. This intermediate reacts with an amine on GRGDS ligand 
(2), yielding a conjugate of the two molecules joined by a stable amide bond [102]. 
  
 
3.3.2 Fluorescent Marker Conjugation 
5-aminoacetamedio fluorescein was conjugated to the bubbles via the 
carbodiimide chemistry described previously. After the 30min EDC surface activation 
step, 5-aminoacetamido was then added at a 1:0.5 molar ratio of peptide to total polymer 
carboxyl groups. Samples were shaken end-over-end for 3 hours, centrifuged and washed 
3 times, frozen and lyophilized for 48 hours. Amount of conjugated marker was 
quantified via flow cytometry. 
 
3.3.3 TRAIL conjugation via maleimide chemistry 
To conjugate TRAIL to the microbubbles using maleimide chemistry (figure 3.2), 
60mg of freeze-dried microbubbles were suspended in 2-(N-morpholino)ethanesulfonic 
acid (MES buffer) (4ml, 50mM, pH 5.2) and shaken to create a suspension. Separately, 
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1ml of deionized water was added to 14.86mg of N-[ß-Maleimidopropionic acid] 
hydrazide (BMPH) for a 25mM BMPH solution. 1ml of deionized water was added to 
19.17mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) for a 
50 mM EDC solution. 1 ml of deionized water was added to 12mg of N-
hydroxysulfosuccinimide  (NHS). To microbubble suspension was added 1ml of the 
BMPH, EDC and NHS solutions. The resulting suspension was shaken on end-over-end 
for 30 minutes. Microbubbles were collected via centrifugation, washed to remove 
unreacted EDC, and pellet resuspended in phosphate buffer solution (PBS, 4ml). To this 
solution was added Tumor necrosis (TNF)-related apoptosis-inducing ligand (1.2μg). The 
suspension was shaken end-over-end for 1.5 hours. Resulting TRAIL conjugated 
microspheres were collected via centrifugation, washed 3 times to remove unbound 
TRAIL, flash frozen, and lyophilized for 48 hrs. For a control microbubble group with 
only physically adsorbed TRAIL the same process was used, but the chemical 
crosslinkers EDC and BMPH were omitted. This conjugation strategy is outlined in detail 
in Appendix B, part B. 
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Figure 3.2: Maleimide coupling reaction. R=TRAIL.  
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3.3.4 Antibody Conjugation via Maleimide or Carbodiimide Chemistry  
 To link antibodies to the microbubbles via a maleimide reaction, free thiols in the 
hinge region of the antibody were created by reduction or reduction/digestion.  
Reduction/digestion procedures were followed according to manufacturer’s guidelines 
(Antibody fragmentation kit, Pierce, Rockford, IL) and are roughly as described in figure 
6.1. 
Fragmented antibodies were conjugated to the surface of the microbubbles via a 
maleimide reaction. 60mg of bubbles were added to 4ml (5.2 pH) MES buffer.  14.86mg 
BMPH, 19.17mg of EDC and 12ml NHS were added to 1 ml of deionized water.  Equal 
amounts of each solution (1ml of BMPH, EDC and NHS) were added to the bubble/MES 
buffer solution and end-over-end mixed for 30 mins for activation of groups. Solutions 
were centrifuged, resuspended and washed. After the final wash bubbles were 
resuspended in 4ml of PBS buffer and fragmented antibody solutions added. After end-
over-end shaking for 3hrs solutions were centrifuged and bubbles washed 3x, flash frozen 
and lyophilized.  
 To link full anti-CA-125 antibodies to microbubbles a carbodiimide reaction was 
utilized. Freeze-dried microbubbles (50mg) were suspended in 2ml of buffer (0.1M MES, 
0.3M NaCl, pH 6.0) in a centrifuge tube. To this 0.8mg of EDC (2mM) and 2.2mg of 
NHS (5mM) was added. The solutions were shaken on an end-over-end shaker for 30 
mins for EDC activation of microbubble surfaces. The solutions were then centrifuged 
and washed 3 times to remove excess EDC. Anti-CA-125 antibody (100μg) was added. 
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Samples were shaken end-over-end for 3 hours, centrifuged and washed 3 times with 
buffer (PBS, pH 7.0), frozen and lyophilized for 48 hours. 
 
3.4 Contrast Agent Characterization  
3.4.1 Dose and Time Response 
A detailed description of the procedure is given in Appendix C.  Briefly, the 
freeze-dried microbubbles were weighed into a custom-made plexi-glass vessel equipped 
with an acoustic window. 100 ml of 37°C phosphate buffered saline (PBS) solution was 
added.  The suspension was then placed in the acoustic set-up as shown in Fig. 3.3.  The 
5MHz single element ultrasound transducer (model V-309, center frequency 5.45 MHz, 
spectrum range 2.95-7.95 MHz, 0.75” diameter) used for acoustic enhancement was 
obtained from Panametrics (Waltham, MA).  This frequency was chosen because it was 
shown to give the maximum enhancement for microbubbles previously developed in our 
laboratory [103]. The pulser/receiver (model 5072 PR, Panametrics, Inc, Waltham, MA) 
was used to pulse the transducer was set with the following parameters: pulse repetition 
frequency=100Hz, energy level=1 (~13 joules), damping level=3, and gain=40dB. These 
settings resulted in a peak pressure of 816 kPa at the focus (45 mm) of the 5MHz, 0.50” 
element diameter transducer [20].  The acoustic enhancement was analyzed using 
LabVIEW programs.  Cumulative dose response curves were constructed for doses in the 
range of 0.015 mg/ml – 0.03 mg/ml at 37°C. Dose responses were performed 
cumulatively because dose response tests generally took less than 5 minutes to perform, 
and the CA was stable (as determined by time response) over this time period.  After 
establishing the dose response curves, time response curves were preformed for the 
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lowest steady state dose.  Time response curves record data points once a minute for 15 
minutes at 37°C.   
 
 5 MHz  
   
Figure 3.3:   In vitro acoustic set up. The 5MHz transducer was inserted in a deionized water bath and 
focused through an acoustic window of a 100ml custom made vessel located at a distance of 45 mm. A 
pulser/receiver was used to pulse the transducers at a pulse repetition frequency of 100 Hz. The received 
signals were amplified to 40 dB and fed to the digital oscilloscope, which is connected to the computer with 
LabView applications.  
 
3.4.2  Environmental Scanning Electron Microscopy 
The environmental scanning electron microscope used to capture images was a 
Phillips XL-30.  Briefly, the samples were secured using carbon tape and gold-palladium 
sputter coated for 100 seconds prior to imaging. The samples were placed in the 
microscope in a round sample holder and put under vacuum. The imaging distance was 
approximately 10mm on the z-axis. After focusing, photos were taken at multiple 
magnifications and saved as high resolution TIF files. 
Panametrics 5072PR 
 
LeCroy 9350A Dell Dimension PC  
Windows XP OS 
LabVIEW 7.1 software GPIB Interface
Transducer 
 
Tank Pulse-Echo Amplified Signal 
Sample Vessel  
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3.4.3 Particle Sizing 
Particle size was measured on a Malvern Nano ZS Particle Sizer (Worcestershire, 
UK) in order to characterize the mean size and distribution of the agent. Roughly one mg 
of dry sample was suspended in 1 ml of deionized water. Each sample was measured 
three times and the number percent results averaged.   
 Particles size and count were also measured using a Coulter Counter. Particles 
were diluted and suspended in electrolyte solution. The particles were drawn through an 
aperture in the glass vessel on the machine. Measurements of size and particle count were 
repeated three times and results averaged.  Data is described in Appendix D. 
 
3.4.4 Antibody Detection 
Quantification of antibody conjugation was assessed indirectly using an Easy-
Titer IgG assay (Pierce Biotechnology, Rockford, IL). The assay gives concentration of 
protein by absorbency. The assay procedure uses monodispersed polystyrene beads 
coated with anti IgG antibodies and absorb light at 340 and 405 nm. When beads are 
mixed with solution containing IgG they aggregate causing decreased adsorption of light. 
The decrease in absorption is proportional to IgG concentration. Standard curves were 
created by serially diluting anti-CA-125 antibody into 96 well plates, applying the Easy-
Titer beads, shaking and measuring at 340/405nm. Samples were measured by collecting 
supernatant from the 3 washes during antibody conjugation, concentrating the solution in 
Amicon ultra filtraton tubes with 30k mW cutoff (Millipore, Billerica, MA), diluting 
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serially into 96 well plates, adding well-mixed Easy-Titer beads, shaking and measuring 
absorbance at 340/405 nm. Calculation of bound antibody was made by indirectly by 
calculating amount of IgG present in supernatant after conjugation.  
  Fluorescence detection was used to assess activity of anti-CA-125 antibody bound 
to microbubbles via incubation with fluorescently labeled CA-125 antigen. CA-125 
antigen (Biodesign, Saco, ME), was fluorescently labeled with AlexaFluor 488-NHS 
(Invitrogen,  Carlsbad, CA). The labeled CA-125 antigen was incubated with anti-CA-
125 conjugated microbubbles for 1.5 hrs, washed 3 times and bubbles resuspended. The 
bubble solutions were diluted into 96 well plates and fluorescence intensity was 
measured. Fluorescence values were compared to those of a standard curve made with 
anti-CA-125 antibody incubated with labeled CA-125 antigen.     
 
3.5  Cellular Analysis 
3.5.1 Fluorescent Microscopy 
Fluorescent microscopy was performed on samples using an Olympus IX80 
microscope with 4x, 10x, 20x and 40x objective lenses and green (FITC), red (TRITC), 
blue (DAPI) filters. The microscope was interfaced to a PC. Images were acquired via 
Spot Advanced acquisition software (Diagnostic Instruments, Sterling Heights, MI).  
 
3.5.2 Flow Cytometry 
Flow cytometry was performed to assess model fluorescent ligand binding using a 
FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Microbubbles 
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were diluted in deionized water prior to placement in the machine. After flow cytometry 
measurement, data was analyzed using FloJo software (Tree Star Inc., Ashland, OR) 
focusing on changes in fluorescence intensity data.  
Measurement of apoptosis in cell populations was achieving using a Guava 
EasyCyte flow cytometer (Guava Technologies, Hayward, CA). After treatments cells 
were detached from plate surface and incubated with florescent tags that indicate stages 
of apoptosis when measured with flow cytometry. Cells were diluted to 500 cells/μl prior 
to measurement. Data was analyzed using Guava analysis software.  
 
3.6 Cell culture and cellular targeting studies 
3.6.1 Cell Culture 
There were 4 cell lines that were cultured in this project. All cell populations were 
incubated at 37°C in 95% humidified air and 5% CO2 and passaged regularly at about 70-
80% confluency. The media used for each cell model are as follows: 
• MDA-MB-231 (human breast): RPMI 1640 90%, 9% Fetal Bovine Serum (FBS), 
1% Penicillin Streptomycin (PS) 
• MCF-7 (human breast): Dulbecco’s Modified Eagle’s Medium (DMEM) 90%, 
9% FBS, 1% PS 
• OVCAR-3 (human ovarian): RPMI 1640 90%, 20% FBS 
• A2058 (human melanoma): Eagle's Minimum Essential Medium (EMEM) 90%, 
9% FBS, 1% PS  
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3.6.2 Static Attachment Studies 
For static attachment studies, cells were seeded on 48 well culture plates and 
permitted to grow to confluence.  On the day of experimentation, special growth medium 
was prepared that contained either the microbubbles contrast agent or modified contrast 
agent in a concentration of 0.5 mg/ml.  The cells were first washed with medium and then 
incubated with the 1ml of contrast agent containing medium for the specified time points.  
Controls included scrambled peptide conjugated microbubbles and unmodified 
microbubbles. For antibody targeting studies, cells were incubated with 0.5mg/ml of 
antibody-modified microbubbles or unmodified microbubbles. All studies were done in 
triplicate. At the specified time point, the medium was removed and the cells were 
washed with 1ml of growth media solution three times.  Quantification of microbubble 
per cell attachment was assessed visually by light/fluorescent microscopy. 
 
3.6.3 Apoptosis Studies 
TRAIL-conjugated microbubbles, TRAIL-adsorbed microbubbles, unmodified 
microbubbles, or TRAIL by itself were incubated (0.5mg/ml or 10ng/well TRAIL) with 
cells and apoptosis was assessed at various timepoints 3, 8, 24, and 48 hours. An 
apoptosis assay was used that detects the externalization of phosphatidylserine in 
apoptotic cells using green-fluorescent Alexa Fluor 488 annexin and red-fluorescent 
propidium iodide nucleic acid stain. Propidium iodide stains necrotic cells with red 
fluorescence. Hoescht blue stain was added to stain the live cells. After treatment, live 
cells are positive for Hoescht stain (blue) negative for both annexin V and PI, early 
apoptotic cells are positive for annexin V (green) only and late apoptotic and necrotic 
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cells are positive for both dyes (green and red). Percent apoptosis was qualitatively 
assessed visually with florescent microscopy.  
For studies evaluating the effect of Velcade on TRAIL-microbubble induced 
apoptosis. A2058 and OVCAR3 cells were grown to 70% confluence in 48 well plates 
(n=3). The cells were treated with either TRAIL, Velcade, TRAIL+Velcade, unmodified 
microbubbles, unmodified microbubbles+Velcade, Mb-TRAIL, Mb-TRAIL+Velcade, or 
left untreated (control). The concentration of agents were 100ng/ml TRAIL, 1μM 
Velcade, and 0.5mg/ml of unmodified or TRAIL modified microbubbles. After 24 
incubation at 37C, 5% CO2, media was aspirated, cells trypsinized, media was replaced, 
200ul was removed from each sample and treated with Guava apoptosis detection 
reagents consisting of Annexin V and 7-AAD. Apoptosis was quantified with flow 
cytometry using Guava EasyCyte flow cytometer. Data was analyzed using Cytosoft 4.1 
software. 
 
3.7 Statistical Testing 
 Statistical analyses were performed using Prism software (San Diego, CA, 
Graphpad Software). ANOVA analysis was used to determine significance. A one-way 
ANOVA was used to test for differences among two or more independent groups. For 
comparison between experimental groups, Tukey’s multiple comparison tests were 
performed and p-values were obtained.  P-values greater than 0.05 were considered 
significant. 
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4. RESULTS AND DISCUSSION: FUNCTIONALIZATION OF 
CONTRAST AGENT SURFACES 
 
A thorough description of the methods, related critical factors, results and analysis 
for each protocol and experiment are described within these chapters.  
The results and discussion section of this thesis is divided into three chapters by 
specific aim. 
• Chapter 4: Functionalization of contrast agent surfaces 
• Chapter 5: A signal-inducing contrast agent 
• Chapter 6: Ultrasound contrast agent for ovarian cancer detection 
 
4.1 Functionalization of Contrast Agent Surfaces 
The first specific aim of this thesis is to develop, optimize and characterize 
methods of making biodegradable polymer contrast agents that have the capacity for 
carrying targeting vectors and to assess cell attachment capabilities of the CA to breast 
cancer cells. 
Degradable microbubbles of poly(lactic-co-glycolic acid) (PLGA) have been 
evaluated for use in a wide variety of specialized drug delivery applications. Investigators 
are approaching the problem of maintaining site specificity for microbubbles delivered by 
intravenous routes by modifying the surface properties of the microbubbles to increase 
their retention in tissues [2, 3, 6, 49, 70, 104]. Of particular interest is modification of the 
microbubble surface with ligands that bind to cell surface receptors. Targeting 
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microbubbles to specific cell types has great potential for increasing the efficiency of 
drug delivery to the desired location, especially for microbubbles delivered intravenously.  
A number of groups have devised techniques for immobilizing ligands to the 
surface of PLGA microbubbles, including biotin-streptavidin complexes and 
carbodiimide coupling of primary amines on the ligand to the carboxylic acid end groups 
on microbubbles made of PLGA [30]. Carboxylated polystyrene microbubbles have been 
used as model particles for targeting studies taking advantage of a high density of 
carboxylic acid groups at the microbubble surface for ligand conjugation by a well-
established carbodiimide chemistry protocol [62]. 
Using carbodiimide chemistry to conjugate ligands to the surface of PLGA  
microbubbles, however, is not as effective as linkage to the surface of the polystyrene 
microbubbles. With carboxylic acid groups only at the end of polymer chains, PLGA 
microbubbles have a limited number of available conjugation sites compared to a model 
like carboxylated polystyrene microbubbles. In addition, common emulsion methods for 
making PLGA microbubbles use surfactants such as poly(vinyl alcohol) (PVA) to 
stabilize the emulsion. PVA has been shown to remain at the surface of the microbubbles, 
even after repeated washing [105], refer to figure 3.1, creating a potential barrier for 
efficient ligand conjugation to the acid end groups of PLGA. 
The goal of specific aim #1 is to create and examine the ligand conjugation properties 
of three different microbubble surfaces: 
1. A surface with an increased number of surface carboxylic acid groups by 
replacing the traditional stabilizer PVA (which has hydroxyl side chains) with a 
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stabilizer bearing carboxylic acid side chains, namely poly(ethylene-alt-maleic 
acid) (PEMA). Section 4.2    
2. A surface with incorporated lipid-PEG-biotin therefore laden with an outer layer 
of biotin available for functionalization by straightforward biotin-avidin coupling 
chemistry. Section 4.3 
3. A surface with a varied, rough geometry, thereby having a greater modifiable 
surface area per microbubble as well as surface projections that may present 
ligands to receptors differently than a smooth-surfaced microbubble would. 
Section 4.4 
 
4.2 Functional group enhancement via surfactant with carboxylic acid end chain 
Protocols for making PLGA microspheres by emulsion techniques commonly use 
surfactants to stabilize the emulsion. Most commonly, poly(vinyl alcohol) (PVA) is used 
as the stabilizer. Other functional groups aside from hydroxyls, however, would be more 
suitable for many surface modification chemistries (see figure 4.1). Poly(ethylene-alt-
maleic acid) (PEMA) is a surfactant with carboxyl end chains. The carboxyl side chains 
of PEMA, present at the microbubble surface, can be linked to primary amine groups of 
the desired ligand, forming stable amide bonds. In work by Keegan et al, PEMA has been 
used successfully to stabilize solid PLGA microspheres [62].  
This group hypothesized that solid PLGA microspheres made with PEMA 
surfactant would have a greater amount of carboxyl groups on its surface and than those 
made with PVA surfactant, and as a result that they could bind more targeting ligands to 
the microspheres. We hypothesized that we could use PEMA as a surfactant to stabilize 
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hollow, echogenic contrast agent microbubbles. Though we were able to create micron 
sized bubbles with complete replacement of PVA by PEMA, these microbubbles were 
not acoustically active. Therefore, we chose to blend the two surfactants in order to 
achieve echogenic microbubbles with PEMA surfactant present on the microbubble 
surface. Further conjugation with a model ligand demonstrated that ligand conjugation 
increased with increasing amounts of PEMA, however cellular attachment did not 
increase with increasing amounts of PEMA. The results of these studies are presented in 
this section. 
        
A B
 
 
Figure 4.1: Suggested arrangement of acid end groups present on the surface of microbubbles made with 
A) PVA and B) PEMA stabilizers. Use of PVA results in hydroxyl surface groups, use of PEMA results in 
carboxylic acid groups. 
 
4.2.1 PEMA Synthesis 
 
Poly(ethylene-alt-maleic acid) was synthesized via ring-opening of poly (ethylene 
maleic anhydride). Two methods of ring opening were tested to create a 1% w/v solution. 
The first ultilized a heating procedure similar to that used to make PVA. Poly (ethylene 
maleic anhydride) was slowly added to deionized water heated to 90 deg. C on a stirplate 
for 6 hours. This resulted in large aggregates of PEMA which did not go into solution. 
The heating procedure was modified by refluxing the solution in bottom flask a fitted 
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with a water-cooled condensation column and heating by means of a heating mantel for 
72 hours. This resulted in smaller aggregates, however PEMA still did not go into 
solution. 
The second attempt was an acid/base ring opening method. Poly (ethylene maleic 
anhydride) was slowly added to a 1M NaOH solution stirring in a round bottom flask for 
24 hours (no heat). This method was successful; the resulting PEMA went into solution. 
After the procedure, pH was corrected to 6.5 and the solution was desalted via dialysis. 
Using the acid/base ring opening method,1, 3, 5 and 7% w/v solutions of PEMA 
were produced.   
 
4.2.2 Complete surfactant replacement in microbubble fabrication 
Following our microbubble fabrication procedure [9], the 50 ml of PVA 
surfactant in the second emulsion step was replaced with 50ml of either a 1, 3 or 5% w/v 
solution of PEMA surfactant. The resulting microbubbles were acoustically and 
morphologically evaluated.   
It should be noted that the molecular weights of the two surfactants are not equal. 
PVA has a molecular weight of ~25,000. PEMA has a molecular weight of ~100,000. 
Therefore, theoretically 4 times more PEMA should be used to achieve the same 
surfactant molarity. However, creating a PEMA solution greater than 7% w/v using the 
ring-opening method of poly(ethylene maleic anhydride) (see materials and methods 
section 3.2.2.1) was not feasible. Therefore the following experiments were performed 
with are only 1-5% PEMA solutions. 
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It was observed that the 1% w/v PEMA surfactant did not fully stabilize the 
second emulsion. There were not enough PEMA groups at 1% w/v concentration for 
uniform stabilization, therefore large spheres of polymer were observed after the second 
emulsion. These spheres of polymer were confirmed by scanning electron microscopy 
(SEM) (Philips XL-30) (figure 4.2, A). The 3% and 5% solutions formed full emulsions 
and the resultant bubbles met size requirements (<8 microns), see figure 4.2.  
 
 
Figure 4.2: Scanning electron micrographs of microbubbles made with (A) 1% PEMA, (B) 3% PEMA, and 
(C) 5% PEMA surfactant. 3000x, sizebar=10microns 
 
 
The microbubbles were tested acoustically using the setup described in materials 
& methods section 3.4.1 . The microbubbles made with 1% and 3% w/v PEMA solutions 
were weakly echogenic, having a maximum enhancement of 2 (±0.8) dB and 8 (±1.4) dB 
respectively. The microbubbles made with the 5% w/v PEMA solution had a maximum 
enhancement of 14 (±1.7) dB, significantly greater than microbubbles made with 1% and 
3% PEMA (p<0.05).  The average enhancement in our traditional microbubbles made 
with a 5% w/v PVA solution was 21 (±1.2) dB [30].  
Therefore, complete replacement of PVA by PEMA surfactant in the second 
emulsion of our microbubble fabrication procedure yielded microbubbles that were not 
strongly echogenic. Due to the tradeoff between extra surface carboxyl groups (PEMA) 
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and the echogenicity of microbubbles (PVA), it was decided to study the effects of 
blending the two surfactants at PEMA:PVA. 
 
4.2.3 Fabrication of microbubbles with blended surfactants 
 Blends of PEMA:PVA surfactant were created as described in materials and 
methods section 3.2.2.1.  Surfactant solutions of volume ratios 0:100, 25:75, 50:50, 75:25 
and 100:0 PEMA:PVA were made with 5% w/v PEMA and 5%w/v PVA. The 5%w/v 
PEMA solution was chosen for further study due to the superior acoustic and 
morphological characteristics over microbubbles made with 1% and 3% w/v PEMA.  
The viscosity of the solutions of the blends linearly decreased with increasing 
PEMA:PVA ratios (Brookhaven viscometer, see figure 4.3) . Microbubble samples were 
fabricated with 50ml of each blended surfactant in second emulsion process.  
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Figure 4.3: Viscosity of PEMA: PVA blended surfactants. Viscosity decreases with increasing percentage 
of PEMA in surfactant. 1 CPS = 1 mPa·s 
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Morphology was assessed using SEM as seen in figure 4.4. The microbubbles 
were spherical and ranged in size from 0.5-8 microns. Microbubble size was confirmed 
by light scattering. Size increased with increasing ratio of PEMA:PVA used in 
microbubble fabrication as seen in figure 4.5, though not significantly (p>0.05) between 
ratios 0:100, 25:75, 50:50 and 75:25. The size of microbubbles made with 100% PEMA 
were significantly larger than those made with the other ratios (p<0.05). Acoustic testing 
revealed that microbubbles made with blended surfactants yielded maximum 
enhancements of: 0:100=21(± 1.5), 25:75=20(± 1.7), 50:50=17(± 1.3), 75:25=8(± 0.9) 
and 100:0 =2(±0.5) dB (see figure 4.6).  Microbubbles made with 75:25 and 100:0 
PEMA:PVA ratios had significantly less maximum acoustic enhancement than bubbles 
made with 0:100 and 25:75 PEMA:PVA ratios (p<0.01), for both pre- and post-
modification with GRGDS.  
 
Figure 4.4: Scanning Electron Micrographs of poly(lactic acid) (PLA end-capped, Mw 84.5kDa) 
microbubbles made using blends of PEMA:PVA as a stabilizer in the second emulsion of the W/O/W 
emulsion. A) 0% PEMA: 100% PVA B) 25% PEMA: 75% PVA C) 50% PEMA: 50% PVA D) 75% 
PEMA: 25% PVA E) 100% PEMA: 0% PVA size bar= 10 microns 
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Figure 4.5: Size distribution (A) measured by light scattering (number percent) of microbubbles made with 
blends of PEMA:PVA surfactant (B) Chart of microbubble diameters (Z-average) by surfactant ratio. ± 
standard error of the mean, n=3. 
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Figure 4.6: Maximum enhancement of microbubbles made with PEMA:PVA blended surfactants. 
Maximum enhancement decreases with increasing amount of PEMA surfactant used in microbubble 
fabrication.  Closed circles: unmodified microbubbles, closed squares microbubbles conjugated with 
GRGDS peptide. ± standard error of the mean, n=3. 
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Therefore, we were able to successfully create echogenic microbubbles with 
blends of surfactants that have the potential to display enhanced functional groups on 
their surface. We hypothesized that having an increased amount of PEMA in the 
microbubble fabrication would yeild more surface carboxyl groups and therefore more 
ligand conjugation to the microbubbles. To confirm this we conjugated a model 
flourescent ligand and assessed conjugation via flow cytometry. 
 
4.2.4 Ligand Conjugation Assessment 
 
The degree of surface modification was assessed using a model fluorescent ligand, 5-
aminoacetamideo fluorescein, which was conjugated to the microbubbles made with 
blended surfactants using the carbodiimide linking chemistry as described in materials 
and methods section 3.3.2.  The control group consisted of microbubbles contacted with 
the model ligand, but without the EDC chemical crosslinker present, to account for non 
specific adsorption. 
Fluorescence of the PEMA:PVA microbubble samples was measured at 492nm using 
a FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Relative ligand 
conjugation was assessed by plotting the geometric mean intensities of the flourescence 
data. (figure 4.7). The rightward shift in the green population in figure 4.6 indicates that 
bubbles made with PEMA (figure 4.7B) held more ligand than bubbles made with PVA 
(figure 4.7A).   There was significantly more conjugated ligand (p<0.05) on 
microbubbles made with 50:50, 75:25, and 100:0 blended PEMA:PVA surfactants over 
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that of microbubbles without PEMA (0:100) and microbubbles made with a 25:100 
volume ratio of PEMA:PVA (see figure 4.8).  
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Figure 4.7: Representative flow cytometry plots of fluorescence shift demonstrating that PEMA (B) 
surfactant enhanced microbubbles held more fluorescent ligand than PVA (A) stabilized microbubbles.  
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Figure 4.8: Fluorescence intensity of microbubbles made with blended surfactants and conjugated with 
marker 5-aminoacetamido fluorescein. Fluorescent marker conjugated with (a) and without (b) (as a 
control) EDC chemical crosslinker. ± standard error of the mean 
 
 
 This experiment confirms that our ligand can be successfully linked to our 
microbubbles via carbodiimide chemistry. It also demonstrates that we have an 
signficantly (p<0.05) increased number of functional groups on the surface with the 
addition of PEMA (above 50% volume ratio PEMA:PVA), since we were able to 
conjugate an increased amount of the fluorescent ligand. We hypothesized that having an 
increased amount of available targeting ligand on our bubbles will allow greater targeted 
microbubble attachment to cellular receptors. We tested this hypothesis with a cellular 
adhesion assay. 
 
4.2.5 Static Adhesion Study with PEMA enhanced GRGDS microbubbles 
The 0:100, 25:75, 50:50, 75:25 and 100:0 of PEMA:PVA microbubbles were 
conjugated with GRGDS using a carbodiimide reaction as described above. MDA-MB-
231 cells were grown in 48well plates in DMEM media supplemented with 10% FBS. 
Microbubble solutions were made with 0.5mg/ml microbubbles in media with the 
additional unmodified microbubble group as a control. At 70% confluency cells were 
incubated with the CA modified media (n=3) for 4 timepoints 0, 5, 10 and 15 minutes. At 
the specified time points media was aspirated and cells washed 2x before imaging using 
light microscopy. Microbubble per cell attachment was assessed through blinded, visual 
inspection of images (figure 4.9). 
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Figure 4.9: Cellular Attachment Testing of PEMA surfactant enhanced ligated microbubbles. MDA-MB-
231 cells incubated with 0.5 mg/ml of microbubbles made with blends of surfactant (a) 0PEMA:100PVA, 
(b) 25PEMA:75PVA, (c) 50PEMA:50PVA, (d) 75PEMA:25PVA, (e) 100PEMA:0PVA and conjugated 
with GRGDS peptide, or (f) unmodified microbubbles.  Pictures taken at 10 mins incubation, 40x, size 
bar=50um. 
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Figure 4.10: Cellular attachment (microbubbles/cell) of GRGDS ligated microbubbles made with 
PEMA:PVA blends of surfactant. ± standard error of the mean.  
 
It was determined that contrary to our hypothesis that increased amounts of 
GRGDS resulting from an increase in of carboxyl groups by PEMA would lead to 
increased attachment, attachment decreased with increasing amounts of PEMA (figure 
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4.10). At 10 and 20 minutes, microbubbles made without PEMA (100% PVA) had 
significantly more microbubble/cell attachment than microbubbles made with 50:50, 
75:25, and 100:0 PEMA:PVA blends (p<0.001 for all groups except 50:50 at 10min 
which was p<0.01). A possible explanation for this phenomenon is that there is an 
optimal density for targeting ligand on the microbubble surface for cellular adhesion. 
This is suggested by several researchers [54, 77].  In a previous study by our group [70] it 
was determined that 0.5 GRGDS groups: total PLA carboxyl groups was optimal for our 
application. In this experiment it was this same ratio that gave the best cellular 
attachment. Perhaps having more carboxyl groups resulted in an oversaturation of 
targeting ligand on the surface of the bubbles. Therefore this may have led to reduced 
bioactivity of GRGDS due to overcrowding on the microbubble, reducing the chance for 
the ligand to adhere to its target.  Other possible explanations include the fact that PEMA 
results in a greater net negative surface charge on the microbubbles, which inhibits 
attraction of the microbubbles to the cells, or that PEMA is deleterious to the health of 
the cells in some fashion that PVA is not.    
 
4.2.6 Conclusion: Functional group enhancement via surfactant with carboxylic acid 
end chains 
 
We were able to produce echogenic ultrasound contrast agents with an enhanced 
ability to carry surface ligands, with agents made using blends of two surfactants, PVA 
(hydroxyl end groups) and PEMA (carboxyl end groups). The acoustic enhancement 
provided by these bubbles decreased with increasing percentage of PEMA surfactant. As 
we hypothesized, agents prepared with greater amounts of PEMA were able to carry 
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more conjugated ligand as determined by flow cytometry, suggesting a greater number of 
carboxyl groups available on the microcapsule surface. However, unexpectedly there was 
a reduction in cellular attachment with increasing amounts of PEMA. A possible 
explanation is that the optimal density of GRGDS was exceeded by increasing the 
amount of available modifiable groups on the microbubbles. 
 
 
4.3 Novel Targeted Lipid-Polymer Microbubbles 
The primary strategy of targeting contrast agents to specific sites involves 
modifying the surface of the contrast agent with ligands.  The techniques of surface 
modification with ligands typically used are either the covalent attachment of ligands, or 
physical incorporation of ligands into the shell of the contrast agent.  The physical 
incorporation of lipid-ligand conjugates has been primarily explored in the formation of 
lipid-based contrast agents. This aim explores the feasibility of combining the physical 
incorporation of lipid-ligand conjugates into polymer ultrasound contrast agents. We 
hypothesize that by adding DSPE(lipid)-PEG-biotin conjugate into the first emulsion, 
with the subsequent association of the conjugate’s lipid portion within the hydrophobic 
polymer shell, we will create bubbles with surface PEG spacer-biotin groups adaptable to 
a variety of biotinlyated targeting molecules. 
4.3.1 Development of DSPE-PEG-Biotin incorporated microbubbles 
Microbubbles were formed in our double emulsion process [70] using either 
ammonium carbonate (BON) or ammonium carbamate (BAM) as a porogen. In order to 
fabricate the biotinylated microcapsules, 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Biotinyl(Polyethylene Glycol)2000] (DSPE-PEG(2000)Biotin) 
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was added to the first mixture of PLA and organic solvent in a 1:100 ratio of 
lipid:polymer.  Briefly, 1mL of 5M solution (5mg lipid / 1mL CHCl3) was aspirated to 
the bottom of a 50ml max beaker with a glass syringe, dried under a stream of argon gas, 
and dessicated under vacuum for 3 hours. The 50 ml beaker containing the dried DSPE-
PEG-Biotin was then used to dissolve the polymer in organic solvent prior to the first 
emulsion. The resulting microbubbles have the DSPE lipid in the shell, a PEG spacer and 
biotin on the surface for modification with streptavidin and further conjugation with a 
biotinylated ligand as seen in figure 4.11 
 
 
Figure 4.11: Schematic of microbubble with incorporated DSPE-PEG-biotin plus streptavidin and 
biotinylated targeting ligand.  
 
4.3.2 Characterization of DSPE-PEG-Biotin incorporated microbubbles 
Biotin presence was confirmed by first incubating the capsules with fluorescently 
labeled streptavidin followed by visualization of fluorescence with a fluorescent 
microscope and confocal microscope. To examine microbubble morphology,  
microcapsules were mounted on metal stubs with double-sided tape and coated with 
platinum for imaging with an SEM.  Additional size information was obtained from light 
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scattering experiments.  In vitro acoustic dose and time response curves were collected 
using our custom built set-up. 
The four varieties of polymer microbubbles fabricated were PLA formed with 
ammonium carbonate as a porogen (PLA-BON), PLA formed with ammonium carbamate 
as a porogen (PLA-BAM), and each of those two formed with the addition of the lipid-
ligand  conjugate (PLA-BON-PEG and PLA-BAM-PEG).  Confocal and fluorescent 
microscopy confirmed the presence of fluorescently labeled streptavidin bound to the 
biotinylated surfaces of PLA-BON-PEG and PLA-BAM-PEG, and not to the control 
microcapsules which lack the DSPE-PEG-Biotin component (figure 4.12)  The PLA-
BAM and PLA-BAM-PEG microbubbles were relatively monodisperse, hollow, with 
smooth surfaces (figure 4.13, A & B).  The PLA-BON and PLA-BON-PEG were 
similarly monodisperse and hollow, but with a rougher surface morphology (figure 4.13, 
C &D).   Light scattering size distributions supported the ESEM observations of 
microbubble diameters ranging from 300nm-2.5 microns. The acoustic signal 
enhancement for the spheres after maximal dose was 18 (±0.6) dB for PLA-BON, 22 
(±1.7) dB for PLA-BON-PEG, 19 (±0.9) dB for PLA-BAM, and 24 (±0.6) dB for PLA-
BAM-PEG (± standard error of the mean, n=3) (figure 4.14, A). There was no significant 
difference in maximum enhancement with the addition of the lipid-ligand conjugate 
(p>0.05). The percent loss of the original signal over 15 minutes was 18% for PLA-BON, 
20% for PLA-BAM, 50% for PLA-BON-PEG, and 60% for PLA-BAM-PEG (figure 
4.14, B).  There was 40% more signal loss from microbubbles made with lipid-ligand 
conjugate after 15 minutes of insonation, significantly greater than that of microbubbles 
made without the conjugate (p<0.01). 
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The time response data follow what would be expected based on the dose 
response data. Addition of lipid into the microbubble shell results in a higher acoustic 
enhancement probably due to the resultant larger, thinner shelled bubbles created by the 
addition of a lipid into the first emulsion. Lipid is a viscosity enhancer, and it has been 
shown that increased viscosity in the polymer phase of an emulsion leads to greater 
microsphere size [106]. These bubbles are also more likely to burst which explains why 
the bubbles with lipid within in the shell lost about 30-40% more signal after 15 minutes 
of insonation than those without lipid.   
 
 
A B
C D
 
 
E 
 
 
Figure 4.12: Fluorescence detection of ligand. Confocal micrographs of microbubbles (A-D). The left 
column is brightfield (A&C), while the right column is fluorescence (B&D). The top column is the control 
of microbubbles without DSPE-PEG-biotin in the shell (A&B) and the bottom column is the experimental 
group of microbubbles with DSPE-PEG-biotin in the shell (C&D) Both control and experimental 
microbubbles were incubated with streptavidin prior to imaging. E) Histogram of the detection of Oregon 
green-labeled Streptavidin bound to microbubbles. The shift in fluorescence with the biotin group shows 
the labeled streptavidin binds to the microbubbles made with DSPE-PEG-biotin, but not control bubbles 
without DSPE-PEG-biotin. 
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Figure 4.13: Scanning Electron Micrographs of (A) PLA-BAM microbubbles, (B)PLA-BAM-PEG 
microbubbles (C) PLA-BON microbubbles, and (D) PLA-BON-PEG microbubbles, depicting 
microbubbles 300nm-2.5microns in size. 6000x, size bar=5 microns.  
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Figure 4.14: Acoustic Testing. Cumulative dose response curve (A) and acoustic stability (B) of 
microbubbles with DSPE-PEG-biotin incorporation (PLA-BAM-PEG, PLA-BON-PEG) and without (PLA-
BAM, PLA-BON). ± standard error of the mean, n=3. 
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4.3.3 Conclusion: DSPE-PEG-Biotin incorporated microbubbles 
Proof of concept studies demonstrate that DSPE-PEG-Biotin conjugates can be 
successfully incorporated into PLA microbubbles without serious effect on echogenicity 
or morphology. In addition, it is noted that the incorporation of the lipid-ligand caused a 
40% decrease in acoustic stability after 15 minutes of insonation. The acoustic response 
of these microcapsules can possibly be tuned by changing amounts of incorporated lipid. 
As demonstrated by fluorescent ligand, this model system can potentially be extended to 
physiologically relevant ligands by either using lipids conjugated to the physiologic 
ligand or linking biotinylated ligands to the current system. This novel approach for 
functionalization of microbubble contrast agents represents a flexible disease targeting 
system; it can be extended for use with any targeting ligand that can be biotinlyated.    
 
4.4 Targeted microbubbles with smooth and rough textured surfaces 
The last component of specific aim 1 was to examine the hypothesis that shape of 
the polymeric contrast agent will have an effect on the adhesion of microbubbles to cells 
due to a change in the presentation the ligand to its target. Researchers have found that 
adhesive properties of lipid-based contrast agents with microvilli-like projected structures 
on their surface enhanced the cellular binding properties of the microbubbles [5]. In our 
laboratory, it has been shown that microbubbles made with polymer PLGA 50:50 can 
produce echogenic particles with a rough architecture of projected structures which 
maintain high echogenicity. In order to compare only the effect of the morphology on 
cellular targeting it was necessary to first produce echogenic microbubbles with both 
smooth and rough surfaces, but made of the same polymer.  
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4.4.1 Development of smooth and rough textured microbubbles 
In order to produce echogenic microbubbles with either smooth or rough surfaces 
using the same polymer a systematic microbubble fabrication study was performed. 
Samples were fabricated by systematically varying both chemical and physical steps in 
our double emulsion process. These included: 
• Inherent viscosity of polymer (PLGA 50:50 from 0.3-0.70 dL/g I.V.) 
• Water to oil ratio (1:10 or 1:20) in first emulsion  
• Surfactant molecular weight (25k or 133k Mw PVA) in second emulsion 
• Porogen types and concentrations (camphor, ammonium carbonate)  
• Homogenization and solvent evaporation parameters 
 
Based on previous work in our laboratory, we were already aware of which 
parameters in fabrication resulted in rough textured microbubbles. In fact, it was applying 
the same fabrication procedure we use to create our spherical PLA based microbubbles to 
PLGA 50:50 (3.5A) polymer.  However, to that date we did not have a method to create 
smooth spherical microbubbles using the PLGA 50:50 polymer. 
Inherent Viscosity. We began by evaluating inherent viscosity of the polymer, 
which equates with the molecular weight. PLGA 50:50 was available from the 
manufacturer (Lakeshore Biomaterials, Birmingham, AL) in 2A, 3.5A, 4A, 5A and 6A 
forms. The number in the designation refers to the range of inherent viscosity and letter 
refers to end group (e.g. 6A is 0.60-0.70 dL/g I.V. with an acid end group). The PLA we 
use to create smooth microbubbles has a much higher I.V. (0.55-0.65 dL/g) than PLGA 
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50:50 3.5A (0.35-0.45 dL/g). Therefore, we decided to evaluate only those polymers with 
I.V.’s equal or greater than 0.35 dL/g. 4A was not evaluated due to its very similar I.V to 
3.5A. We fabricated microbubbles using 3.5A, 5A and 6A PLGA 50:50 polymers.  See 
table 3.1 for a list of polymers and characteristics. 
Water:Oil Ratio. It has been shown that the oil-phase volume plays a critical role 
in determining morphology. Yang et al. varied oil phase volume (9,12 and 15 ml) in their 
double emulsion process to produce microspheres [107]. They found that a microspheres 
with a low oil volume yielded microspheres with numerous pores. They reasoned that 
since a low methylene chloride (oil) content results in a more viscous solution, it was 
more difficult to break up the internal water into smaller droplets in the first emulsion. 
The larger water droplets left empty spaces after freeze-drying creating the pores. Also 
since water has a high surface energy, it was likely that the internal droplets coalesced 
with one another when the oil volume was low, yielding a porous internal matrix [107]. 
Since we are seeking to reduce the porosity, we chose to evaluate doubling our oil 
volume in the water:oil ratio from 1:10 water:oil to 1:20 water:oil. 
Surfactant concentration. In order to form spherical particles it is essential to 
have enough stabilization groups in the surfactant. In the past our lab has evaluated a 
6,000, 25,000 and 133,000 Mw PVA for creating microbubbles [14]. We hypothesized 
that increasing the size of the PVA would help stabilize the microbubbles and retain the 
smooth surface in the second emulsion. It has been shown that due to the high molecular 
weight of PVA, its presence in the external water phase of the double emulsion may 
increase the emulsion viscosity which increases difficulty of breaking the emulsion into 
smaller droplets and may lead to increased microbubble size [107]. Offsetting this is the 
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stabilization effect of the PVA in the external water phase, stabilizing the emulsion 
droplets against coalescence, resulting in smaller stabilized droplets  [107]. To increase 
the stabilization effect and create spherical microbubbles, we’ve chosen to test a higher, 
133,000 Mw surfactant along with our traditional 25,000 Mw PVA.  To account for the 
predicted increase in particle size due to an increase in emulsion viscosity from higher 
Mw PVA, a higher homogenization speed, 10,500 rpm, was used to break up the more 
viscous emulsion. 
Porogen Types and Concentrations. Past research in our laboratory has 
demonstrated that acoustic properties can be tweaked by varying the sublimable core and 
shell porosity of the microbubble [20].  Originally, our process uses a 40 mg/ml 
concentration of ammonium carbonate and the 50mg of camphor in the shell. It is known 
that without ammonium carbonate and camphor in the double emulsion process, smooth 
but solid microspheres are formed [11, 62]. Solid microspheres are not echogenic. We 
hypothesized that by incrementally increasing the amount of ammonium carbonate and 
camphor from 0 (smooth solid/not echogenic) up to the original concentration 
(rough/echogenic) in increments of 25mg for camphor and 20mg/ml ammonium 
carbonate (1M), we can create hollow smooth surfaced echogenic microbubbles.   
Homogenization/Solvent Evaporation. Lastly, we evaluated physical parameters 
for creation of smooth microbubbles. We chose to increase at homogenization speed 
because a faster rate of homogenization can help the second emulsion form and stabilize 
micron sized bubbles. Furthermore, increasing the viscosity of the polymer and of the 
surfactant creates a more viscous emulsion that must be homogenized at a higher speed in 
order to break up the larger droplets. We increased the rate from 9500 rpm to 10500 rpm, 
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however we could not further increase due to equipment limitations. Because the bubbles 
are not yet hardened during the 1.5 hour solvent evaporation step, we decreased the 
stirplate speed from 800 to 400 rpm to make the conditions less harsh, but still stirring at 
a rate fast enough for proper evaporation of solvent. We hypothesized that the 
microbubbles may be smoother with reduced stirspeed because they aren’t colliding as 
much with other bubbles. 
 Using the above mentioned parameters we created the samples described in Table 
4.1. Acoustic testing and SEM was used to screen each sample. 
 
4.4.2 Characterization smooth and rough surfaced microbubbles 
Characterization included size analysis with dynamic light scattering, acoustic 
testing in our custom setup, and morphology analysis using SEM.   
 
Table 4.1: Parameters for Smooth/Rough surface microbubble fabrication study and corresponding 
acoustic enhancement and morphology observations for each experimental group. * samples not imaged 
 
No. Name 
Solvent 
(ml) 
PVA 
Mw Camphor Porogen 
Stir/Homo. 
Rpm 
Max 
dB Morphology 
1 3.5A 10 133k 25mg 20mg/ml 400 / 10500 7 very rough  
2 3.5A 10 25k 25mg 20mg/ml 400 / 10500 6 very rough  
3 3.5A 10 133k 50mg 40mg/ml 400 / 10500 12 * 
4 3.5A 10 25k 50mg 40mg/ml 400 / 10500 20±1.1 Rough 
5 3.5A 20 133k 25mg 20mg/ml 400 / 10500 8 round rough 
6 3.5A 20 25k 25mg 20mg/ml 400 / 10500 11 * 
7 3.5A 20 133k 50mg 40mg/ml 400 / 10500 12 round rough 
8 3.5A 20 25k 50mg 40mg/ml 400 / 10500 17 Rough 
9 5A 20 133k 25mg 20mg/ml 400 / 10500 16 semi-smooth 
10 5A 20 25k 25mg 20mg/ml 400 / 10500 18 less rough 
11 5A 20 133k 50mg 40mg/ml 400 / 10500 15 semi-smooth 
12 5A 20 25k 50mg 40mg/ml 400 / 10500 19 Rough 
19 6A 20 133k 25mg 20mg/ml 400 / 10500 18±0.8 smooth 
20 6A 20 133k 50mg 40mg/ml 400 / 10500 19 semi-smooth 
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 We began our study by varying each of our parameters solvent amount, PVA Mw, 
camphor and porogen for the 3.5A polymer. As expected using the original microbubble 
fabrication procedure applied to the 3.5A polymer created echogenic (20±1.1 dB) rough 
microbubbles. We found that the most spherical appearing particles, though still rough 
surfaced, were created with the 1:20 ratio of water:oil (solvent). We chose to use 20ml of 
solvent for the 5A polymer, varying only the surfactants and porogens. After this 
experiment we noted that those microbubbles made with the 133k Mw surfactant had 
semi-smooth surfaces. Testing our last and highest I.V. polymer, 6A, we chose to fix both 
solvent and surfactant varying only porogen amounts. It was found that the 6A sample 
with higher amounts of porogen was slightly more echogenic than that with less porogen, 
however its surface was not as smooth, so the 6A sample with half the amount of 
porogens was chosen for further study. 
SEM demonstrated smooth and rough morphologies from PLGA 50:50 
microbubbles (figure 4.16, A & D).  The size distribution of the 20 samples described in 
table 4.1 is depicted figure 4.15A and shows a general size range of 0.3-6 microns for all 
the various samples. The size distribution of the microbubbles made with the chosen 
parameters for smooth and rough morphology is seen in figure 4.15B. Mean diameter for 
these smooth microbubbles was 2.86 ± 0.2 microns, and for the rough microbubbles the 
mean diameter was 4.1 ± 0.3 microns (z-average, ± standard error of the mean, n=3). The 
optimal fabrication parameters selected to create smooth and rough surfaced PLGA 50:50 
microbubbles are summarized in table 4.2. The optimal parameters for making smooth 
and rough surfaced bubbles from the PLGA 50:50 polymer were as hypothesized.  
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Figure 4.15: Size distribution by number as determined by light scattering for (A) all variants (1-20) of 
PLGA 50:50 microbubbles, and (B) chosen smooth and rough surfaced PLGA 50:50 microbubbles.  
 
 
Table 4.2: The fabrication parameters selected for fabrication of smooth, column (A), and rough, column 
(B), surfaced PLGA 50:50 microbubbles.  
 
 (A) Smooth (B) Rough 
Polymer I.V.  0.60-0.70 dL/g 0.30-0.40 dL/g 
Water : Oil 1:20 1:10 
Ammonium Carbonate 20 mg/ml 40 mg/ml 
Camphor 25mg 50mg 
PVA Mw (Da) 133,000 25,000 
Homogenization Speed 10,500 RPM 9,500 RPM 
Stirplate Speed during 
Solvent Evaporation  
400  RPM 800 RPM 
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4.4.3 Cellular adhesion of targeted smooth and rough surfaced microbubbles 
These above described agents were chosen for ligand conjugation with either the 
peptide GRGDS or a scrambled peptide GRDGS using a covalent carbodiimide linkage. 
These GRGDS modified microbubbles should have an affinity to the αvβ3 receptors 
present on cancer cells. MDA-MB-231 human breast cancer cells were grown in 48 well 
plates until 70% confluence. Solutions of cellular media made with 0.5 mg/ml of the 
modified (RGD/scrambled) or unmodified microbubbles were incubated on the cells for 
0,10,20 or 60 min (37degC, 5% CO2). After washing cells were examined under light 
microscopy (figure 4.16, B,C,E F) and binding quantified with blinded visual inspection 
(figure 4.17).  
 
For all time points past 0 min the GRGDS ligated rough textured microbubbles 
had significant cellular attachment over the controls of unmodified microbubbles and 
microbubbles conjugated with a scrambled peptide (p < 0.05). Furthermore, at 20 and 60 
minutes the GRGDS ligated rough textured microbubbles had significantly greater 
cellular attachment than the GRGDS ligated smooth surfaced bubbles (p <0.05). (one-
way ANOVA, Tukey’s multiple comparison test). It should be noted that the unmodfieid 
rough textured microbubbles exhibited greater cellular attachment than the unmodified 
smooth microbubbles and scrambled peptide-modified smooth mirobubbles, however this 
difference in attachment was not statistically significant (p>0.05).   
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Figure 4.16: SEM of smooth and rough microbubbles with corresponding light micrographs demonstrating 
cellular attachment of the modified and unmodified agents to MDA-MB-231 cells. A) SEM smooth 
bubbles, size bar =10um, B) Light micrograph of unmodified smooth CA incubated on cells C) Light 
micrograph of RGD modified smooth CA incubated on cells D) SEM of rough bubbles, size bar=10um, E) 
Light micrograph of unmodified rough CA incubated on cells C) Light micrograph of RGD modified rough 
CA incubated on cells (all cellular photos taken after 20 min incubation). 
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Figure 4.17: Microbubble attachment/cell of smooth and rough surfaced microbubbles (Mb), unligated 
(Mb-unmod), modified with a scrambled peptide (Mb-ScramPep), or modified with GRGDS peptide (Mb-
RGD). Filled symbol indicates rough texture, open symbol indicates smooth textured microbubbles. 
Incubated with 0.5mg/ml CA, evaluated at 0,10,20 and 60 min. n=3 ± standard error of the mean. 
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4.4.4 Conclusion: Smooth and rough surfaces microbubbles for targeting 
It has been shown that through the systematic analysis of chemical and physical 
parameters in the fabrication process it is possible to create echogenic PLGA 50:50 
contrast agents with both smooth and rough surfaces. Furthermore we demonstrated that 
conjugation with GRGDS allowed attachment of these agents to αvβ3 expressing breast 
cancer cells, with microbubble/cell attachment of rough-CA significant (p<0.05) as 
compared to smooth CA at both 20 and 60 minutes incubation. Similar studies performed 
by Rychak et al [8] offer an explanation of this observed phenomenon.  
Rychak et al. claims that the outward projected structures on their microbubbles 
reduced the force on the adhesive bond of antibody to target by increasing the lever arm 
between the center of the microbubble and the rearmost anchoring bond. They calculated 
that a microbubble bound by a single antibody molecule located at the tip of a 0.5 micron 
wrinkle experiences a ~55% lower bond force than a spherical microbubble in which the 
ligand is flush with the surface. This reduced load due to lever arm resulted in increased 
bubble stabilization; they found that their wrinkled bubbles remained adherent long 
enough for additional stabilizing bonds to form. However, they could not conclude 
whether it was the geometry alone or the deformable nature of the wrinkled bubbles that 
was ultimately responsible for the sustained adhesion. To compare our findings to 
Rychak’s, the projected structures as seen in figure 4.18 are also in the 0.5 micron range.  
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Figure 4.18: SEM of rough surfaced microbubbles demonstrating projected surface elements in the 0.5 
micron range. 6000x, sizebar=5microns. 
 
We found that at 20 and 60 minutes of incubation we had significant (p<0.05) 
cellular attachment of our GRGDS ligated rough microbubbles compared to GRGDS 
ligated-smooth microbubbles. Rychak’s model predicted that the projections in the 
microbubbles increased sustained adherence since it allowed the particle to stay attached 
long enough for stabilized bonds to form. We believe that our increased adhesion may be 
due to the same phenomenon, though it should be noted that their model was based on 
liposomes and that the deformability of a polymer-shelled agent is less than a lipid-
shelled agent. 
Alternatively, the observation that unmodified rough textured microbubbles 
exhibitied greater cellular attachment than unmodified smooth microbubbles suggests 
there could be greater entanglement with the rough textured microbubbles within the 
glycocalyx layer at the cellular surface. Glycocalyx is a carbohydrate-rich zone on the 
cell exterior, mainly consisting of glycoproteins and proteoglycans. The glycocalyx on 
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the surface of cells is partly responsible for the adhesive properties of the cell and carries 
a net negative charge [108]. A model by Agarwal et al. suggests that glycocalyx presence 
on the endothelial cell surface has an effect on the binding of nanocarriers [109]. Leung 
et al. states that any increase in contact area and establishment of physical entanglement 
at the interface strengthens the force of cellular adhesion [108]. Hence, factors that favor 
enhanced physical entanglement, such as our rough textured microbubbles, could 
potentially increase cellular adhesion strength. 
 
 
4.5 Conclusion: Surface functionalized microbubbles 
Specific aim 1 evaluated three new methods of enhancing the surface of our 
microbubbles for cellular targeting purposes. The first method enhanced the ability of our 
agent to carry targeting ligands by the addition of PEMA, a carboxyl containing 
surfactant. This surfactant was successfully used to form solid PLGA microspheres [62], 
but has never been applied to polymer based contrast agents. Furthermore, this research 
presents the first example blending PVA and PEMA surfactants to create acoustically 
active contrast agents and is the first to examine the effects of the surfactant blends on 
CA size, morphology, acoustic properties and RGD mediated cellular adhesion to αvβ3 
receptors in breast cancer cells. For this application, increased surface ligands did not 
lead to an increase in cellular attachment. This may be attributed to an oversaturation of 
surface-bound ligands leading to overcrowding, hence hindering the ligand from 
attaching to its target and reducing cellular adhesion.  Other possible explanations include 
the fact that PEMA results in a greater net negative surface charge on the microbubbles, 
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which inhibits attraction of the microbubbles to the cells, or that PEMA is deleterious to 
the health of the cells in some fashion that PVA is not.    
 The second method was the evaluation of the incorporation of a lipid conjugated 
with PEG and a functional group into the shell of our CA microbubbles. Though this 
concept has been demonstrated in solid microspheres [11], this thesis presents the first 
report of using lipid-PEG-biotin to functionalize a contrast agent platform. As the lipid 
preferentially associated with the polymer shell, it created a PEG layer with surface 
modifiable groups (biotin). Incorporation of the lipid did not significantly affect the CA’s 
maximum acoustic enhancement (p>0.05), however it significantly reduce its stability 
over 15 minutes of insonation by 30-40% (p<0.05). This incoporated lipid-conjugate 
concept could be extended to create other functional groups on the microbubble surface 
and hence the CA could be tailored for a variety or targeting ligands. 
 The last method of surface functionalization explored the cellular attachment 
behavior of microbubbles with varied morphological features. A systematic study of 
varying microbubble fabrication parameters produced echogenic microbubbles made of 
PLGA 50:50 polymer with either a rough surfaced or smooth surfaced morphology. 
Cellular attachment studies revealed that rough textured microbubbles that were ligated 
with GRGDS exhibitied significant (p<0.05) cellular adhesion over smooth ligated 
microbubbles and controls at 20 and 60 mins. It was noted that even without ligation, 
rough microbubbles tended to adhere more the cells. Reasons for this behavior may be 
the deformability of the rough microbubbles allowing the extended features holding the 
ligand to reach its integrin target or alternatively that the morphology of the rough bubble 
creates entanglement within the glycocalyx layer surrounding the cells.  
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Specific Aim 1 demonstrated that our polymeric ultrasound contrast agent 
platform is highly adaptable. It can be tuned to various applications by changing the 
functional groups available on its surface through surfactants or incorporation of lipid 
conjugates as well as modifying its morphology to improve cellular adhesion. 
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5. RESULTS AND DISCUSSION: A SIGNAL-INDUCING 
ULTRASOUND CONTRAST AGENT 
 
 
5.1 A signal-inducing ultrasound contrast agent 
 
The goal of specific Aim #2 was to develop methods to produce a novel bioactive 
ultrasound contrast agent that elicits signal transduction, using TNF related apoptosis-
inducing ligand (TRAIL also known as Apo-2L) and apoptosis as a model. This was done 
by first conjugating TRAIL to microbubbles using maleimide chemistry and then 
assessing the apoptotic inducing ability of TRAIL-microbubbles on TRAIL-sensitive cell 
populations. We hypothesized apoptosis of cancer cells via signal transduction can be 
achieved by incubation with TRAIL-conjugated microbubbles. 
TRAIL/ Apoptosis was chosen as a model for several reasons. It is well 
documented that TRAIL induces cell death selectivity in tumor cells [86, 110, 111]. 
There are death receptors (DR4 and DR5) for TRAIL on normal cells, however 
protection of normal tissues happens by way of decoy receptors (DcRs), which compete 
with DR4 and DR5 for binding to TRAIL (see figure 5.1,B) . DcR1 and DcR2 are cell 
surface protein resembling DR4 and DR5, but lack cytoplasmic components. DR4 and 
DR5 are expressed in normal tissue and in many types of tumor cells, whereas DcR1 and 
DcR2 are expressed frequently in normal cells but infrequently in tumor cells [88]. This 
differential expression of death and decoy receptors enables TRAIL to induce apoptosis 
in tumors while sparing normal cells. The first reason TRAIL was chosen for our 
application was this cell selectivity, a desirable attribute, since our agent is administered 
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systemically. The TRAIL-microbubbles will theoretically induce apoptosis in only tumor 
cells.  
Furthermore, TRAIL-microbubbles may enter and be retained within tumor 
tissue. While some believe that micron-sized contrast agents remain only within the 
vasculature, it is a possibility that populations of the microbubbles may be able to 
extravasate into tissue from the large pores of leaky tumor vasculature. When aggregates 
of tumor cells achieve a diameter of 1-2mm they require neovasculature to supply 
nutrients. These vessels have an irregular, incomplete structure that includes pores. Yuan 
et al. found the size of tumor vessel pores in LS174T human colon adenocarcinoma 
implanted in the dorsal skin chambers in immunodeficient mice could be as large as 0.4 
microns in diameter [33 background]. Using SEM, researchers have identified structural 
abnormalities in the endothelium of tumor vasculature including cellular openings with a 
mean diameter of 1.7 microns (range, 0.3-4.7 microns) [39-42]. If the microbubbles can 
escape the tumor vasculature, TRAIL would be able to reach its receptors and exert its 
effects. Coincidentally retention of the microbubbles in tumors is enhanced through the 
retention mechanisms at play in the enhanced permeability and retention (EPR) effect 
[42]. 
Lastly, we considered the benefit of delivering apoptosis inducing TRAIL on an 
ultrasound contrast agent platform. There have been several studies investigating the 
effect of ultrasound and ultrasound contrast agents on cellular apoptosis [81, 82]. Feril et 
al. [81] investigated the effects of ultrasound contrast agents on ultrasound induced 
apoptosis in human lymphoma cells, determining that Optison was effective in 
augmenting ultrasound induced cell death due to the cavitation of the agent. A similar 
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study by Honda et al. [82] evaluating the effect of free radial formation during cavitation, 
found that ultrasound induced apoptosis of cancer cells was linked to cavitation. When 
their cells were insonated in the presence of Levovist; synergistic enhancement of cell 
death was observed at concentrations of more than 20 mg/mL [82]. This results suggest 
that contrast agents, acting as cavitation nuclei, can enhance ultrasound-induced 
apoptosis due to an increase in cell membrane damage. Therefore, there is added 
apoptotic benefit to delivering TRAIL via an ultrasound contrast agent platform over 
TRAIL therapy alone.  
Currently, there is no published research regarding the use of pro-apoptotic 
agents, such as TRAIL, as a ligand on an ultrasound contrast agent.  Furthermore, we 
present a method of enhancing TRAIL-Mb apoptosis by the synergistic effect of 
concurrent treatment by a proteasome inhibitor, Velcade (Millenium Pharmaceuticals, 
Cambridge, MA).  There is currently no published research on the Velcade-enhanced 
TRAIL apoptosis using TRAIL on a polymeric carrier. 
 
 
 
  
 
Figure 5.1: Schematic of apoptosis inducing polymeric contrast agent. A) TRAIL is conjugated to the PLA 
microbubble with a BMPH linking arm. Binding of TRAIL-CA to receptors on cancer cells induces 
apoptosis. B) TRAIL receptors and decoy receptors present on cellular surface, DR4 and DR5 binding 
trigger caspase signaling cascade and apoptosis. 
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5.1.1 Conjugation of TRAIL to microbubbles 
 
As a proof of concept, a method of coupling TRAIL to PLA microbubbles was 
established using a maleimide reaction with a BMPH heterobifunctional spacer arm (8.1 
angstroms in length). Control samples were also made with TRAIL but without the 
BMPH chemical crosslinking agent in the conjugation process, therefore any TRAIL 
present is not chemically linked to the bubble, only adsorbed.  
 
 Briefly, to conjugate TRAIL to the microbubbles using maleimide chemistry, 
60mg of freeze-dried microbubbles were suspended in 4ml MES buffer. 1ml of deionized 
water was added to 14.86mg of BMPH (25mM) and 1ml of deionized water was also 
added to 19.17mg EDC (50 mM). Equal amounts of the BMPH solution (0.5ml) and the 
EDC solution (1ml) were added to microbubble suspensions and shaken on end-over-end 
for 30 minutes to activate surfaces. Microbubbles were collected via centrifugation, 
washed 3 times to remove unreacted EDC, and resuspended in PBS. TRAIL was added 
(1.2μg) and suspension shaken end-over-end for 1.5 hours. Resulting TRAIL conjugated 
microspheres were collected via centrifugation, washed 3 times to remove unbound 
TRAIL, flash frozen, and lyophilized for 48 hrs. For a control microbubble group with 
only physically adsorbed TRAIL, the same process was repeated with the omission of 
chemical linkers EDC and BMPH.  
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5.1.2 Cellular studies with TRAIL-microbubbles and Velcade 
To establish a proof of concept we used a breast cancer cell line, MDA-MB-231, 
which has receptors for TRAIL and with which we had significant experience. Once 
confirming that it was possible to induce apoptosis by TRAIL-Mb in breast cancer cells 
by fluorescent microscopy, we chose to expand the focus of this thesis to other cancers, 
namely ovarian cancer and melanoma.  
In our second experiment we grew these two cancer cell lines, OVCAR-3 and 
A2058, and evaluated the amount of live, dead and apoptotic cells once exposed to 
TRAIL-Mb at various time points using fluorescent microscopy.  
Based on these findings we decided to explore options for enhancing the 
apoptosis capability of our TRAIL-Mb. Proteasome inhibitors have emerged as a way to 
enhance TRAIL based treatments [89, 90, 95]. The mechanism by which proteasome 
inhibitors enhance TRAIL apoptosis is explained in detail in figure 2.3. Briefly, TRAIL 
triggers an external apoptosis mechanism by creating a caspase cascade once bound to its 
DR4/DR5 receptor. However, not all tumors respond to TRAIL. This lack of response 
may be attributed either to unfavorable ratios of death and decoy receptors or because of 
intracellular resistance mechanisms [112]. With respect to intracellular resistance 
mechanisms, the FLIP protein has been identified as a blocker of apoptosis induced by 
TNF family death receptors. FLIP binds to and neutralizes pro-caspase and pro-apoptotic 
proteins normally recruited to the cytosolic domains of apoptosis-inducing TRAIL 
receptors upon ligand stimulation, thus interrupting early steps in TRAIL signaling. 
Furthermore, overexpression of FLIP protein has been documented in cancers. 
Proteasome inhibitors like Velcade trigger angiogenesis intrinsically by spurring the 
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release of pro-apoptotic proteins from mitochondria. Therefore, the internal signaling 
mechanism of Velcade helps overcome TRAIL intracellular TRAIL resistance and 
synergistically causes apoptosis in cancer cells. Millenium Pharmaceuticals graciously 
supplied us with their proteasome inhibitor, Velcade, which is currently undergoing 
clinical trials.  
Looking for a robust way to quantitatively measure the apoptotic effects of 
TRAIL-Mb and TRAIL-Mb + Velcade on Ovarian and Melanoma cancer cells, we 
decided to move from fluorescent microscopy to flow cytometry. Our third experiment is 
the flow cytometry based apoptosis measurement of ovarian and melanoma cancer cells 
treated with TRAIL-Mb with and without Velcade. 
Prior to starting studies with TRAIL-Mb and Velcade we performed several proof 
of concept experiments of TRAIL-Mb induced apoptosis which are discussed in the 
sections following. 
 
 
5.2 TRAIL-induced apoptosis in breast cancer cell model 
 MDA-MB-231 breast cancer cells were grown in 48 well plates. TRAIL 
conjugated microbubbles were incubated (0.5mg/ml) with MDA-MB-231 breast cancer 
cells and apoptosis was assessed at 3, 24 and 48 hours. Several TRAIL induced apoptosis 
studies assessed apoptosis at 24 hours [85, 89, 113]. Therefore this time point was tested 
along with an earlier and later time point to observe shorter and longer term effects. We 
used an apoptosis assay that detects the externalization of phosphatidylserine in apoptotic 
cells using green-fluorescent Alexa Fluor 488 annexin and red-fluorescent propidium 
iodide nucleic acid stain. Propidium iodide stains necrotic cells with red fluorescence. 
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After treatment, live cells are negative for both annexin V and PI, early apoptotic cells 
are positive for annexin V (green) only and late apoptotic and necrotic cells are positive 
for both dyes (green and red). The results seen in figure 5.2 demonstrate that there is little 
apoptosis in the controls of unmodified bubbles and bubbles made without crosslinking 
agents (figure 5.2, A&B respectively). The control group of TRAIL applied directly to 
the cells (no microbubbles present) and the experimental group of microbubbles 
conjugated with TRAIL (figure 5.2, C&D respectively) showed similar amounts of 
apoptotic activity (p= 0.58) as quantified by counting the fluorescently labeled apoptotic 
cells in each population (assay performed at 3 hours, t-test, n=3).  
 
 
 
Figure 5.2: Fluorescence Imaging of MDA-MB-231 human breast cancer cells incubated with A) 
unmodified microbubbles B) adsorbed TRAIL on microbubbles (conjugated without chemical linker)  C) 
TRAIL ligand alone (no microbubbles) D) Microbubbles conjugated with TRAIL. Timepoint for all 
images= 3 hrs. Green indicates apoptotic cell, red indicates dead cell, and green & red together indicates 
late apoptotic or dead cell. 
 
 
Therefore we have demonstrated the proof of concept that TRAIL conjugated to a 
polymeric ultrasound contrast agent can induce apoptosis in breast cancer cells and that 
conjugating the TRAIL ligand to a CA not diminish its abilities as a pro-apoptotic agent. 
For our next experiment we move from breast cancer to ovarian and melanoma cancer 
cells. We also add a live-cell stain to evaluate the relative amount of live cells in each 
treated population. 
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5.3 TRAIL induced apoptosis on melanoma and ovarian cancer cells by microscopy  
Two cell lines were chosen for this experiment. OVCAR-3 ovarian cancer cells 
are epithelial type derived from adenocarcinoma. They are resistant to clinically relevant 
concentrations of adriamycin, melphalan and cisplatin and often used as a model system 
in which to study drug resistance in ovarian cancer [114]. OVCAR-3 are known to have 
DR4 receptors as reported by Siervo et al. [113].  A2058 melanoma skin cancer cells are 
derived from metastatic lymph node site. They are noted to be a highly invasive cell line 
[114], and have also been shown to have DR4 receptors present on their surface [115]. 
 To qualitatively assess apoptosis induced by Mb-TRAIL by fluorescent 
microscopy, OVCAR-3 nd A2058 cells were first seeded in 48 well plates (n=3) and at 
80% confluency were aspirated and treated with modified media supplemented with 0.5 
mg/ml Mb. Sample groups included untreated cells, microbubbles only, TRAIL only, 
TRAIL- microbubbles made without crosslinkers, and TRAIL modified microbubbles. At 
timepoints 3, 12, and 24 hrs modified media were aspirated off the cells and cells were 
washed. The study timepoints were shortened to 24 hrs from the previous breast cancer 
cell study because of the non-sterile microbubbles. Following protocol from Invitrogen 
(Vybrant apoptosis assay kit #2 V13241), cells were stained with Annexin V (green), PI 
(red), and live cell stain Hoescht (blue) dye.  
 Fluorescent Microcopy results for A2058 melanoma are depicted in figure 5.3 and 
from OVCAR-3 are seen in figure 5.4. Green color indicates apoptotic cell, pink color 
indicates dead cell, green/pink indicates late apoptotic or dead cell and blue indicates live 
cell. Photographs are all at 24 hrs incubation. 
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Figure 5.3: Fluorescence Imaging of OVCAR-3 ovarian cells A) untreated  B) treated with Mb-only C) 
adsorbed TRAIL on microbubbles (conjugated without chemical linker)  D) TRAIL ligand alone (no 
microbubbles) E) Microbubbles conjugated with TRAIL. Timepoint for all images= 24 hrs. Green indicates 
apoptotic cell, pink indicates dead cell, green & red together indicates late apoptotic or dead cell, blue 
indicates live cell. 10x, sizebar=200um 
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Figure 5.4:  Fluorescence Imaging of A2058 Melanoma cells A) untreated  B) treated with Mb-only C) 
adsorbed TRAIL on microbubbles (conjugated without chemical linker)  D) TRAIL ligand alone (no 
microbubbles) E) Microbubbles conjugated with TRAIL. Timepoint for all images= 24 hrs. Green indicates 
apoptotic cell, pink indicates dead cell, green & red together indicates late apoptotic or dead cell, blue 
indicates live cell. 10x, sizebar=200um 
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These results were very encouraging. Both OVCAR-3 and A2058 experienced 
greater amounts of apoptosis once exposed to TRAIL-Mb than Mb alone and Mb with 
adsorbed TRAIL, as measured by visual inspection. Also, it appears that they also 
experience similar or greater amounts of apoptosis than treatment with TRAIL alone (at 
an equal concentration to that present on the Mb in each sample), though this statement 
will have to be confirmed with quantitative evidence (flow cytometry).  
It should be noted that even after 24 hours of incubation with TRAIL and TRAIL-
modified Mb there is a large population of alive (blue) OVCAR-3 and A2058 cells 
resistant to apoptosis. Ovarian cancer cells are known to be resistant to common anti-
cancer agents, however they have had some limited success with TRAIL based therapy 
[116]. Researchers have examined sensitizing OVCAR-3 to TRAIL induced apoptosis 
using proteasome inhibitors [116]. Melanoma cells are more susceptible to TRAIL-
induced apoptosis, however apoptosis may also be enhanced in this population using a 
proteasome inhibitor like Velcade.  
 
 
5.4 TRAIL induced apoptosis on melanoma and ovarian cancer cells by flow 
cytometry  
To quantitatively assess the amount of apoptosis induced by TRAIL-Mb and TRAIL-
Mb + Velcade of OVCAR-3 cells and A2058 cells, flow cytometry studies were 
performed.  
To prepare OVCAR-3 and A2058 cells were first seeded in 12 well plates (n=3) and 
at 80% confluency were aspirated and treated with TRAIL, Velcade, microbubble 
modified media, or combinations of these treatments. Sample groups included: Untreated 
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cells, cells treated with Velcade only (1μM), cells treated with TRAIL only (100ng/ml), 
cells treated with Velcade + TRAIL, cells treated with microbubbles (0.5mg/ml) only, 
cells treated with microbubbles + Velcade, cells treated with TRAIL-modified 
microbubbles (0.5mg/ml), and lastly cells treated with TRAIL-modified microbubbles + 
Velcade. 
After 24 hours of incubation, cells were aspirated (saving the old media that may 
contain dead/apoptotic cells) and trypsinized. 100ul of well mixed cells was added to 
100ul of Guava Nexin Reagent consisting of Annexin V and 7-AAD stain,  and incubated 
for 20 mins at room temperature in the dark.  
Measurement of apoptosis in cell populations was achieving using a Guava EasyCyte 
flow cytometer. Cells were diluted to 500 cells/μl prior to measurement. Data was 
analyzed using Guava analysis software. 
The analysis from Guava software plotting Annexin V vs. 7-AAD staining for 
OVCAR-3 cells is displayed in figure 5.5, and A2058 in figure 5.7. In these diagrams 
viable cells appear in the bottom left hand quadrant, apoptotic cells in the bottom right 
hand quadrant and dead/necrotic cells in the top right quadrant. Quadrants were 
determined by first calibrating the instrument with a positive and negative control.  The 
corresponding numerical data appears in graphical form in figure 5.6 for OVCAR-3 and 
in figure 5.8 for A2058. 
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Figure 5.5: Flow cytometry dot plots of Annexin V staining vs. 7-AAD of OVCAR-3 ovarian cancer cells 
after treatment at 24 hours with (A) Untreated (B) TRAIL only (C) Velcade Only (D) TRAIL + Velcade 
(E) unmodified microbubbles (F) unmodified microbubbles + Velcade (G) TRAIL modified microbubbles 
(H)  TRAIL modified microbubbles + Velcade. Top right quadrant refers to dead cells, bottom left with 
viable cells, and bottom right with apoptotic cells.  
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Figure 5.6: Cell death of OVCAR-3 ovarian cancer cells after 24 hour treatment with TRAIL, Velcade, 
Unmodified microbubbles, TRAIL modified microbubbles or combinations of treatments as indicated. ± 
standard error of the mean, n=3.  
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Figure 5.7: Flow cytometry dot plots of Annexin V staining vs. 7-AAD of A2058 melanoma cells after 
treatment at 24 hours with (A) Untreated (B) TRAIL only (C) Velcade Only (D) TRAIL + Velcade (E) 
unmodified microbubbles (F) unmodified microbubbles + Velcade (G) TRAIL modified microbubbles (H)  
TRAIL modified microbubbles + Velcade. Top right quadrant refers to dead cells, bottom left with viable 
cells, and bottom right with apoptotic cells. 
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Figure 5.8: Cell death of A2058 melanoma cells after 24 hour treatment with TRAIL, Velcade, unmodified 
microbubbles, TRAIL modified microbubbles or combinations of treatments as indicated. ± standard error 
of the mean, n=3.  
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 Flow cytometry of treated OVCAR-3 cells revealed that TRAIL-Mb have 
significant (p<0.05) apoptotic effect as compared to control of unmodified-Mb. This 
finding is in agreement with florescent microscopy observations. However, there was not 
a significant (p>0.05) synergistic apoptotic effect from TRAIL and Velcade treatment by 
themselves or Mb-TRAIL + Velcade, though there was a slight additive effect. 
OVCAR-3 has shown limited sensitivity to TRAIL. Lane et al. states that intrinsic 
(natural) resistance to TRAIL-induced apoptosis occurs in 50% of ovarian carcinoma cell 
lines [116]  and that the molecular mechanisms underlying this resistant TRAIL 
phenotype in human ovarian carcinoma cells is  still unclear. Unlike the results we found, 
Lane et al. found that the addition of proteasome inhibitors to a TRAIL-resistant line of 
OVCAR-3 cells they created resulted in 40–50% more cell death at 24 hrs [116]. 
However, we did find cell viability results similar to that of Kim et al [112] after 
treatment with TRAIL. They found that after 24 hours of incubation with 100ng/ml of 
TRAIL, OVCAR-3 had a cell viability of 30%, which is in agreement with our result that 
70% of OVCAR-3 cells died after 24 hrs of TRAIL (100ng/ml) incubation.  
The A2058 cells treated with Mb-TRAIL + Velcade had significantly (p<0.01) 
more cell death than Mb-TRAIL. This phenomenon was also observed in the control 
groups of Velcade and TRAIL only on A2058 cells. The cells treated with TRAIL 
(100ng/ml) and Velcade (1μM) underwent apoptosis significant (p<0.001) from TRAIL 
treatment or Velcade treatment alone. Therefore, flow cytometry of treated A2058 cells 
revealed that there was a significant TRAIL + Velcade apoptotic effect. Lastly, it was 
confirmed as observed in fluorescent microscopy that  cells treated with Mb-TRAIL 
underwent apoptosis significantly different (p<0.01) from unmodified Mb.   
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Though there is not literature on the TRAIL sensitization of A2058 cells by 
proteasome inhibitors, there is a study of TRAIL sensitization of A2058 cells by E1A 
oncogene [117]. Since E1A does not function within the ubiquitin-proteasome pathway, 
their results are not comparable to our results with Velcade. However, in this study by 
Routes et al. they found that ~50% of A2058 melanoma cells underwent cell death after 
treatment with 100ng/ml TRAIL (16hrs) [117]. This is very similar to our finding that 
50% of A2058 cells died after treatment with 100ng/ml TRAIL (24 hrs).   
 
5.5 Conclusion: A signal-inducing ultrasound contrast agent 
 In this research we have successfully developed a signal-inducing ultrasound 
contrast agent using TRAIL/apoptosis as a model. There is benefit to having TRAIL 
targeted to receptors via a microbubble platform. For the microbubble, TRAIL is a 
relatively biologically safe targeting ligand for systemic administration because it exerts 
its effects selectively in cancer cells.  For TRAIL, an ultrasound contrast agent platform 
could allow the ligand to reach its targets outside the leaky tumor vasculature and be 
retained via EPR effect. Also, the apoptosis of the targeted cancer cells could be 
enhanced by cavitation of the microbubble under insonation causing membrane damage 
and cell death. Lastly, for cancers that are TRAIL resistant having a platform with dual 
TRAIL and Velcade delivery would be ideal. That is, Velcade could be loaded into the 
shell of our microbubbles and TRAIL bound to its surface, allowing the exploitation the 
synergistic apoptotic effect of TRAIL and Velcade if it exists for the particular cell line. 
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6. RESULTS AND DISCUSSION: AN ULTRASOUND CONTRAST 
AGENT FOR OVARIAN CANCER DETECTION 
 
 
 
6.1 Ultrasound contrast agent for ovarian cancer detection 
The goal of the third specific aim in this thesis is the development of an 
ultrasound contrast agent for detection of ovarian cancer.  
Ovarian cancer (OC) is the second most common and most lethal gynecologic 
malignancy in the USA [96]  Over 70% of women with OC are diagnosed with advanced 
stage disease, with a 5 year survival rate 30%. This 5 year survival rate is 90% when 
diagnosed early (disease confined to the ovaries), but only 25% of cases are found in this 
early stage. Partly due to a lack of symptoms and early screening procedures, OC 
incidence rates remain high and mortality rates are virtually unchanged over the last 30 
years [96]. Clinicians currently screen for OC by measuring CA-125 levels in the blood 
(elevated in most women with OC) in combination with transvaginal ultrasound. 
However, there is a need for more robust early OC detection methods.  
We decided to pursue this goal using CA-125 as our model target receptor. CA-
125 is a biomarker for ovarian cancer. CA-125 is expressed as a membrane-bound 
receptor at the surface of cells or is released in soluble form into bodily fluids [96].  CA-
125 is a biomarker with a broad range of utility; risk, early detection, diagnosis, 
prognosis and monitoring. It also represents an attractive therapeutic target and therefore 
is studied as a target in this thesis. In order to target this receptor we chose to use as a 
ligand the anti-CA-125 antibody, OC125.  
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There is no reported research on the development of a targeted ultrasound contrast 
agent for ovarian cancer.  There are however, several CA-125 therapies under 
development that support the possibility of creating a CA-125 antigen targeted contrast 
agent using an anti-CA-125 antibody. Researchers have demonstrated target-specific 
polymeric micelles that can detect specific target proteins such as ovarian cancer-specific 
antigen CA-125 in vitro from serum [118]. Targeted therapies with anti-CA-125 
antibodies conjugated to anti-cancer drugs are currently under study in animal models. A 
recent publication compares the toxicity and efficacy of two such antibodies and reported 
efficacy in vitro and in vivo [99]. Lastly, efforts have been undertaken to develop anti-
CA-125 antibodies specific for the cell-associated form of the antigen, which is of 
particular interest in the future for a targeted applications such as ours [100].  
 
6.1.2 Project Summary and Challenges 
This project’s primary challenge was finding a proper method for antibody 
conjugation that would allow the antibody to be efficiently coupled to the microbubble in 
a manner that would not affect its bioactivity.  The project has had several setbacks. This 
section will describe the actions/experiments taken to correct them.    
To summarize what will be described in this chapter, it was decided that digestion and/or 
digestion and reduction of the antibody would allow it to be conjugated to the bubble at 
its hinge region only using a maleimide coupling reaction. Anti-CA-125 antibody was 
from Biocare, Inc and was reduced or reduced/digested and maleimide conjugated to 
bubbles. Immunohistochemical (IHC)studies were performed by incubating bubbles on 
slices of CA-125 positive tumor tissue and treating with secondary antibody 
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chromophore to see if the CA-125 targeted bubbles bound specifically to CA-125 
positive areas of slices. Unfortunately the IHC process was too harsh for the bubbles, 
requiring solvents that dissolved them. However, it was discovered that in sample tissues 
treated with the reduced Ab-microbubbles CA-125 areas were lightly stained, indicating 
post conjugation activity of reduced but not reduced digested antibody, so reduced 
antibody only was chosen for future studies. 
The static cell attachment study of digested antibody microbubbles revealed no 
significant cellular adhesion. Re-evaluating our processes we discovered that the protein 
BSA was used by the suppliers as a preservative in the CA-125 antibody and, therefore 
BSA may interfere with the conjugation of CA-125 to our bubbles.  Co-conjugation could 
easily obscure the antibody active sites, preventing close contact between the ligand and 
the cell surface receptor.   A BSA-free anti-CA-125 antibody supplied by  QED 
Biosciences was identified,  This antibody was reduced, conjugated to the microbubbles, 
and the resulting activity was studied via a cellular attachment study. Neither method 
demonstrated significant results. Since the reduced Ab was bound to the surface at the 
hinge region, we concluded that perhaps the remaining Fc fragment of the reduced Ab is 
causing steric hindrance, blocking the Ab’s active site and reducing bioactivity.   
We decided to move on and attempt conjugating the full anti-CA-125 antibody using a 
carbodiimide reaction. Conjugating full antibodies by carbodiimide chemistry for 
targeting purposes has been used successfully by other researchers, but it has the 
drawback of random conjugation. Ottoboni et al. used a carbodiimide conjugation to 
create solid microspheres linked with full antibodies directed towards ICAM-1 and 
VCAM-1 [119]. By assay, we found that we were able to achieve excellent conjugation 
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efficiency of the full antibody to the microbubbles using this strategy. Finally, we 
performed static attachment studies with full anti-CA-125 antibody conjugated 
microbubbles and found significant binding to CA-125+ and not CA125- cells. 
  
6.2 Experimental methods and results 
6.2.1 Antibody preparation and maleimide conjugation 
Commercially available anti-CA-125 antibody was obtained from Biocare, Inc. 
and two fragments of the antibody were made for further testing, a reduced antibody (Fab 
retaining the Fc portion) and a reduced and digested antibody (Fab). Procedures were 
followed according to manufacturer’s guidelines (Antibody fragmentation kit, Pierce, 
Rockford, IL) and are roughly as described in figure 6.1. 
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Figure 6.1: Schematic of antibody digestion and reduction. 
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Antibodies were fragmented in order to expose the free thiol groups in the hinge region 
for conjugation. Fragmented antibodies were conjugated to the surface of the 
microbubbles via a maleimide reaction. Briefly, 60mg of bubbles was added to 4ml MES 
buffer (5.2pH).  14.86mg BMPH and 19.17mg of EDC were added to 1 ml of deionized 
water  (for 25umol BMPH, 50umol EDC solutions), equal solutions (0.5ml each) of 
BMPH and EDC were added to the bubble/MES buffer solution and end-over-end mixed 
for 30 mins for activation of groups. Solutions were centrifuged, resuspended and washed 
3x. After final wash bubbles were resuspended in 4ml of PBS buffer and antibody 
solutions added. After end-over-end shaking for 3hrs solutions were centrifuged and 
bubbles washed 3x, frozen and lyophilized.  
 
6.2.2 Immunohistochemical analysis  
 To test the hypothesis that microbubbles conjugated with CA-125 antibody 
fragments will adhere specifically to areas of CA-125 expression in ovarian cancer tissue 
IHC was performed. Tumors were excised from patients (Dr. Brooks, DUCOM), sliced, 
fixed, and assayed to determine CA-125 expression. The slices were made serially to 
ensure they would have corresponding areas of CA-125 expression. CA-125 was stained 
by applying anti-CA-125 antibody and applying a secondary antibody/chromophore 
(DAB). Tissue slices were exposed to digested and reduced anti-CA-125-Mb, reduced 
anti-CA-125-Mb, and unmodified Mb (control) prior to IHC chemical staining. Areas of 
the Mb attachment will be correlated with known CA-125 positive areas through visual 
inspection. A schematic of the envisioned staining procedure is seen in figure 6.2. 
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Figure 6.2: Schematic of immunhistochemical studies. Full anti-CA-125 antibodies and microbubbles with 
fragmented antibodies will bind to CA-125 positive cells. A secondary Ab with chromophore will attach to 
the anti-CA-125 antibodies and create a brown stain. Unmodified microbubbles will not cause staining. 
 
 
The resulting micrographs were not as expected. Microbubbles were not present, 
and it was assumed they were dissolved in the solvent based washing steps of the IHC 
procedure. Staining of the CA-125 receptors was successful in tissue, seen as the brown 
colored areas in figure (6.3, A). Though microbubbles were not seen in the microbubble 
incubated tissue slices (data not shown), CA-125 staining was visible in tissue slices 
incubated with reduced-antibody microbubbles as seen in figure (6.3, B). This staining 
was not seen in reduced-digested samples (figure 6.3, C), therefore we decided to 
discontinue reduced and digested antibody and continue studies with reduced antibody. 
Based on the results of this experiment, IHC analysis of microbubble cellular adhesion 
was discontinued.  Because of the harsh solvents and numerous wash steps involved in 
IHC, we chose to move onto static attachment studies to evaluate microbubble cellular 
adhesion. 
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Figure 6.3: Immunohistochemical staining of excised CA-125 receptor positive tumor tissue with 
secondary antibody- DAB chromophore. (A) anti-CA-125 antibody (B) reduced anti-CA-125 antibody 
conjugated microbubbles (C) reduced and digested anti-CA-125 antibody conjugated microbubbles.   
 
6.2.3 Static attachment studies of reduced-anti-CA-125 antibody microbubbles 
 We discovered through a first unsuccessful static attachment study that we have 
BSA preservative in our bulk solvent of CA-125 antibody that may interfere with 
conjugation. We changed antibody manufacturers to QED Biosciences, Inc. The new CA-
125 antibody was reduced and maleimide conjugated to the microbubbles. Another static 
attachment study was performed using OVCAR-3 (CA-125+) and A2058 (CA-125-) 
cells. 
  Cells were plated in 48 well plates (n=3). Reduced-CA-125 antibody conjugated 
microbubbles and unmodified microbubbles (0.5 mg/ml) were incubated on the each cell 
lines for 0,15,30, and 60 minutes. After each time point cells were washed and imaged 
with light microscopy. Attachment was assessed through visual inspection. 
 The results showed that there was no significant attachment of any microbubble 
population to CA-125+ or CA-125- cells. We decided to test the activity of the reduced-
antibody once conjugated to the bubbles by determining its antigen binding ability. 
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6.2.4 Conjugation of Full anti-CA-125 antibody, with incorporated Nile Red 
Because of our unexpected results using fragmented antibodies we decided to try 
conjugating the full, unfragmented anti-CA-125 antibody to our microbubbles by 
carbodiimide chemistry. This method has been used successfully by other researchers to 
conjugate antibodies to particles, but it has the drawback of random conjugation to amine 
groups present on the antibody.  
Prior to conjugation it was also decided to incorporate nile red, a marker not 
fluorescent in aqueous phases, into microbubbles for imaging purposes. Nile red was 
added to organic phase of the first emulsion 1:100 w/w ratio with PLA.  
Conjugation of the full antibody was completed by suspending nile-red loaded 
freeze-dried microbubbles (50mg) in 2ml of MES buffer (pH 6.0) in a centrifuge tube. To 
this 0.8mg of EDC (2mM) and 2.2mg of NHS (5mM) was added. The solutions were 
shaken on an end-over-end shaker for 30 mins for EDC activation of microbubble 
surfaces. The solutions were then centrifuged and washed 3 times to remove excess EDC. 
100ug of full anti-CA-125 antibody was added to the sample. Samples were shaken end-
over-end for 3 hours, centrifuged and washed 3 times with PBS buffer (pH 7.0), frozen 
and lyophilized for 48 hours. 
 
6.2.5 Characterization of full anti-CA-125 antibody on microbubbles 
By antibody assay, we found that we were able to achieve excellent conjugation 
efficiency of the full antibody to the microbubbles. Supernatant from the 3 wash steps in 
the conjugation procedure was concentrated in amicon tubes with a molecular weight 
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cutoff filter and then diluted into 96 well plate.  Pierce Easy-Titer antibody assay kit 
beads were applied, incubated on a shaker and absorbance measurement by made by plate 
reader. The Easy-Titer IgG assay kit (Pierce) measures concentration of protein by 
absorbency. The assay uses monodispersed polystyrene beads coated with anti-IgG Ab 
that absorb light at 340 and 405 nm. When beads are mixed with a sample containing 
IgG, they aggregate, causing decreased absorption of light. Low IgG concentrations yield 
high absorbance values and high IgG concentrations yield low absorbance values. The 
decrease in absorption is proportional to IgG concentration. 
We developed a standard curve with full CA-125 antibody, figure 6.4. The 
calculated absorbance was 0.88±0.05 (n=6). We calculated, based on pierce protocol, that 
approximately 70μg of the original 100μg of full CA-125 antibody was conjugated to the 
bubbles; a 70% conjugation efficiency.   
 
 
 
Figure 6.4: Standard curve of absorbance vs. CA-125 antibody concentration for antibody assay, Easy-
Titer kit (Pierce, Rockford, IL) .  
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6.2.6 Static Cellular Attachment Study of full anti-CA-125 conjugated microbubbles 
 
 The last experiment of this chapter is the evaluation of cellular attachment to 
OVCAR-3 (CA-125+) and A2058 (CA-125-) cells by full anti-CA-125 antibody 
conjugated microbubbles. We have confirmed that these bubbles have antibody 
conjugated to their surfaces. We proceeded by seeding the two cell lines in 48 well plates. 
Full-CA-125 antibody conjugated microbubbles and unmodified microbubbles (0.5 
mg/ml) were incubated on the each cell lines for 0,15, 30, and 60 minutes. After each 
time point cells were washed and imaged by both light and fluorescent microscopy. 
Attachment was assessed through visual inspection; counting the number of nile red 
fluorescent microbubbles attached to the cells. An example image of the nile-red loaded 
targeted anti-CA-125 antibody microbubbles binding to ovarian cancer cells (15 minute 
time point) is seen in figure 6.5. 
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Figure 6.5: Light micrograph with fluorescent micrograph overlay of OVCAR-3 cells at 15 mins exposure 
to anti-CA-125 antibody conjugated microbubbles.  
 
 
 Quantification of cellular attachment demonstrated that using the full-CA-125 
antibody as a ligand on our microbubbles enabled our microbubbles to bind significantly 
to CA-125 positive ovarian cancer cells. Significant cellular attachment of antibody 
conjugated microbubbles over controls was observed at 30 min (p<0.05) and 60 min 
(p<0.01) as seen in figure 6.6. 
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Figure 6.6: Microbubble/cellular attachment of anti-CA-125 antibody conjugated microbubbles or 
unmodified microbubbles on CA-125+ (OVCAR-3) or CA-125- (A2058) cells at 0,15,30 and 60 mins 
incubation. ± standard error of the mean. 
 
 
6.3 Conclusion: targeted ultrasound contrast agent for early detection of ovarian 
cancer 
This research presents a novel method that can potentially be used for early 
detection of ovarian cancer. Currently, there is no published research on a targeted 
ultrasound contrast agent for ovarian cancer. This technology could perhaps be used for 
intraperitoneal injection for surface lesion detection since epithelial ovarian cancer 
comprises the majority of malignant ovarian tumors [96]. Targeting could also be 
possible if the contrast agent were able to escape out of the leaky tumor vasculature, a 
possibility that may be enhanced by ultrasound treatment. Lastly, this targeting technique 
could perhaps be combined with another therapy for ovarian cancers such as loading of 
Velcade/TRAIL for targeted delivery to chemo-resistant ovarian cancer tumors.  
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7. CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
 
 
7.1 Conclusions and Contributions to Science 
The overall objective of this thesis was to develop in vitro improved PLGA based 
microbubble CAs that facilitate efficient targeting to molecular markers enabling the 
early detection and potentially treatment of malignancies.  
This research examined the engineering of particle surfaces. It demonstrates that 
adding modifiable carboxyl groups to surfaces via a surfactant allows more targeting 
ligand to be conjugated, but does not improve cellular targeting.  It presents a physical 
method to add modifiable PEG-biotin surface groups successfully. Also developed were 
methods to produce rough surfaced microbubbles which had significant cellular binding 
over smooth surfaced microbubbles once modified.  
Introduced was a novel ultrasound contrast agent that acts via signal transduction. 
The TRAIL-modified agent induced a signaling cascade resulting in apoptosis in breast, 
ovarian and skin cancer cells. Furthermore, TRAIL-modified agents exhibited synergistic 
apoptotic effects when combined with the proteasome inhibitor Velcade. 
Lastly, this thesis presents an ultrasound contrast agent targeted to CA-125 
receptors in ovarian cancer which has the potential to enable early detection of the 
disease. 
The various aspects of this research are being conducted in hopes of combining 
them in the future with drug delivery. This would bring together the advantages of site-
targeting, drug delivery, and signal transduction along with the valuable benefits of 
ultrasound. 
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Overall in the field of ultrasound contrast agents this research is unique because 
of its hollow polymeric contrast agent platform, new adaptable surface functionalization 
techniques, cellular signal-inducing capabilities and its novel targets and ligands for 
breast, ovarian and skin cancer detection and treatment. 
 
7.2 Future Recomendations 
Future recommendations for research include combining the cellular targeting 
methods developed in this thesis with ultrasound-triggered drug delivery. Drugs could be 
loaded into the microbubble prior to conjugation with a targeting ligand. Once ligated 
these receptor-targeted drug loaded contrast agents could be exposed to cells and drug 
delivery assessed. An early proof of concept is presented in appendix E.. Once these 
methods are established, the research could continue into small animal investigations to 
establish in vivo safety and efficacy of these targeted drug delivery agents while under 
insonation. 
Specific Aim 2 presents the never before reported use of TRAIL as surface bound 
ligand on an ultrasound contrast agent, creating an apoptotic signaling agent. Hence, this 
is also the first report of proteasome inhibitors (Velcade) being used in combination with 
a TRAIL-ligated ultrasound contrast agents for exploitation of the synergistic apoptotic 
effect of proteasome inhibitors + TRAIL. Having the TRAIL on an ultrasound contrast 
agent may also potentiate the apoptotic effect, as there are reports that contrast agents by 
themselves can enhance apoptosis. Though delivery of Velcade on a polymer platform 
has not yet been reported, perhaps in the future a TRAIL-targeted contrast agent loaded 
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with Velcade could be created. If effective, this therapy could be used for a variety of 
malignancies resistant to traditional chemotherapy treatments. 
The targeting methods developed in this thesis would also be beneficial for future 
adaptation to nano-scale agents. Moving to a nano-scale would allow easier extravasation 
out of tumor vasculature allowing the CAs to reach the tumor tissue. Being able to reach 
the tumor tissue opens the doors to targets that are not present within the vasculature. 
Binding to these targets by nanobubbles could be achieved by surface modification with 
ligands. This thesis demonstrates the adaptability of our polymeric ultrasound contrast 
agent for modification with targeting ligands (e.g. GRGDS peptide and anti-CA-125 
antibodies) and signaling ligands (e.g. TRAIL).   
Lastly, sterilization methods should also be explored. Most sterilization methods, 
especially those involving heat, lead to polymer degradation and subsequent loss of 
acoustic enhancement from our microbubbles. Recently, plasma sterilization has emerged 
as a possible way to sterlize our microbubbles. This method has the potential benefit of 
creating functional groups (carboxyl) on the microbubble surface. The effectiveness of 
the plasma as a sterilization method should be investigated, along with the changes in 
functional groups on the surface, which may also alter the cellular attachment properties 
of the contrast agent once ligated.  
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Appendix A: Protocol for Preparing Microcapsules 
 
 Preparing fresh microcapsules is essential for all studies and takes about three 
hours if done in triplicate. 
1. Weigh out the following chemicals: polymer (0.5g, record lot number as well), 
and porogens ammonium carbamate (0.78g) or ammonium carbonate (0.4g) and 
camphor  (0.05g-if used)  
a. Note: Polymer should always be brought to room temp. before opening so 
that condensation does not form on the beads and cause degradation. For 
convenience you should take ~5g out of the stock solution and place it in a 
sealed glass vial in the refrigerator.  
2. Combine the polymer and 10ml of methylene chloride in a beaker (40ml max 
volume) with a stir bar and stir on a magnetic stir plate, cover with a layer of wax 
paper topped by a layer of parafilm, until camphor and polymer are dissolved 
(~15min). 
a. Note: The ratio of polymer to solvent should is important. If the cover 
opens during stirring, some methylene chloride may evaporate. You 
should be careful, but if needed you can add more methylene chloride to 
bring the level to 10ml after stirring. Also, remember to wear gloves when 
using methylene chloride.   
3. Combine porogen with 10ml of deionized water in a beaker (40ml max volume) 
with a stir bar and stir on a magnetic stir plate. 
4. Measure out 50ml of 5% poly vinyl alcohol (PVA) and put it in a beaker (600ml 
max volume) and place it in the refrigerator. 
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5. Measure out 100ml of 2% isopropyl alcohol (IPA) and keep it in the graduated 
cylinder. 
6. When the camphor and polymer are dissolved, remove stir bar and put in 1ml of 
the porogen solution and sonicate with Misonix probe sonicator at 110W for 30 
seconds. Sonicate in an ice bath 3 seconds on 1 second off. 
7. After sonication, pour the solution into the cold PVA and homogenize with 
Brinkmann PT 3100 homogenizer with attached Polytron PT-DA 3020/2 
generator for 5 minutes at 9,500 rpm. 
8. After homogenization, pour the 100ml of IPA in the solution, add a larger stir bar, 
and stir on a magnetic stir plate for 1 hour.  Make sure the vortex spans the 
diameter of the beaker so the solvent can fully evaporate. 
a. After homogenization remove the blade and pour the IPA over it into the 
beaker to prevent the loss of yield. 
9. After an hour, combine the solution in at least 4 centrifuge tubes (50ml max 
volume) and then centrifuge for 5 minutes at 5,000 rpm (the equivalent of 
approximately 5,000 g). 
10. Decant the liquid and combine the microcapsules into 1 tube and recentrifuge for 
5 minutes at 5,000 rpm. 
11. Decant the liquid and wash the microcapsules three times with hexane. Lay the 
centrifuge tube under the hood and let excess solvent evaporate for about 30 min. 
12. When the microcapsules appear to be thick and pasty, add water and recentrifuge 
for 5 minutes at 5,000 rpm.  
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13. Decant the water, mix (fluff) the microcapsules, put a kimwipe on top of the tube 
with a rubber band, and flash freeze using nitrogen (swirling the tube in nitrogen 
to create a cone shaped pellet). 
14. Put the frozen microcapsules in a freeze dryer vessel and on the freeze dryer for at 
least 48 hours. 
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Appendix B: Chemical Conjugation Methods 
 
Conjugating ligands to polymer microbubbles occurs after the microbubbles have already 
been made.   
 
Part A: Carbodiimide Conjugation 
1. Weigh out 50mg of freeze-dried microbubbles into a centrifuge tube 
2. Weigh out 0.8mg of EDC and 2.2mg of NHS 
3. Add 2ml of buffer to the centrifuge tube with microbubbles(0.1M MES pH 5.2) 
4. To this solution add the 0.8mg of EDC (2mM) and 2.2mg of NHS (5mM) 
5. Shake this solution on an end over end shaker for 30 mins for EDC activation of 
the microbubble surfaces. 
6. Centrifuge the solution and wash to remove excess EDC 
7. Add ligand: Add GRGDS peptide or 5-aminoacetamedio fluorescein at a 1:0.5 
molar ratio of peptide to total polymer carboxyl groups. For antibody conjugation 
add 100ug of anti-CA-125 antibody 
8. Shake the samples on an end-over-end shaker for 1.5 hours. If the sample is 
fluorescent, wrap the centrifuge tubes in aluminum foil to protect from light. 
9. Centrifuge to collect and washed 3 times with buffer (PBS, pH 7.0) to remove 
unbound ligand. 
10.  Freeze the samples with liquid nitrogen, swirling the centrifuge tube to create a 
cone shaped pellet 
11.  Uncap the centrifuge tube, cover with a kimwipe and lyophilize the sample for 48 
hours.  
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Part B: Maleimide Conjugation 
1. Weigh out two 60 mg of freeze-dried microbubbles into a centrifuge tube  
2. Add to the microbubble sample 4ml of MES buffer (pH 5.2)  
3. Weigh out BMPH (14.86 mg, 25mM) and EDC (19.17mg, 50mM) and NHS 
(12mg, NHS:EDC ratio of 0.6) into eppendorf tubes 
4. Add1ml DI water to each eppendorf tube (BMPH, EDC and NHS)  
5. Add 1ml of each solution (BMPH, EDC and NHS) into the centrifuge tube 
containing the suspension of 60mg microbubbles in 4ml MES. For control 
samples made without crosslinkers, omit these agents. 
6. Shake on end-over-end shaker for 30 mins. 
7. Centrifuge and wash to remove unreacted BMPH (washed with PBS).  
8. Resuspend pellet in 2mL of PBS 
9. Add ligand: 1.2μg of TRAIL or fragmented antibody 
10. Shake sample end over end for 1.5 hours  
11. Add thioglycolic acid (5mM, 50μl) to vial to stop reaction 
12.  Shake sample end over end for 10 mins. 
13. Centrifuge, wash 3x, flash freeze by swirling in tube in liguid nitrogen, and 
lyophilize for 48 hours.  
 
Note: Thioglycolic acid  (92.12 Mw). We want to use 5mM in the conjugation, but 
0.347μl of acid is too small to measure out, so a stock solution is made and used by:  
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1. Make 0.1M stock solution by adding 5ul of acid to 720 ul of DI water.  
2. Add 50μl to each centrifuge tube to stop maleimide conjugation process 
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Appendix C: Protocol for Conducting Dose and Time Response 
 
 
The purpose of the dose response is to find the optimum dose where the 
ultrasound enhancement is the maximum.  The purpose of a time response is to measure 
acoustic stability of the contrast agent.  The time response should be done following a 
dose response at a dose less than the maximum dose on the linear portion of the dose 
response curve. 
 
For Dose Response: 
1. Weigh out 3mg of contrast agent and suspend it in 200µl of Phosphate Buffered 
Saline (PBS pH 7.4).  This is your stock solution. 
2. Fill the sample vessel with 100 ml of PBS and a small stir bar, turn on the 
oscilloscope and pulser, and focus the sample vessel.  
3. For each dose, starting with 0.003mg/ml, inject 20µl of stock solution into the 
sample vessel and begin the LabView computer program. 
4. Run the program. 
5. For the next dose, 0.006mg/ml, inject another 20µl of stock solution into the 
sample vessel.  Do not remove the original contents if this is a cumulative dose 
response. 
6. Continue dose response up to 0.03mg/ml or until shadowing is evident. 
 
Computer Operation for Dose Response: 
1. Create a folder with appropriate subfolders. 
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2. Open up the Main Ultrasound Program from LabVIEW and then open up the 
Main Ultrasound Program.vi. 
3. Using the open file program, choose a directory path in which the data should be 
saved by opening the folder path, selecting which folder to save the data in, and 
hitting select current directory. 
4. To begin taking the dose response, push the Run button. 
5. When completed, to view the results, first under the Analyze Data tab, push 
Export Calculated Text and chose a folder to save the data to. 
6. To view results, open up the dose data file using Excel and the enhancement in 
will be displayed for each dose in mV and dB.  
 
For Time Response: 
1. Choose dose on the dose response curve that is not the maximum (it should be on 
the linear part of the curve) and prepare a solution of that concentration, using 
procedure described above in the dose response section. 
2. Fill the sample vessel with 100 ml of PBS and a small stir bar, turn on the 
oscilloscope and pulser, and focus the sample vessel.  
3. Inject dose into the sample vessel and begin the LabView computer program 
(Main Ultrasound Program.vi). 
4. Run the program for 15 minutes. 
 
Computer Operation for Time Response: 
1. Create a folder with appropriate subfolders. 
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2. Open up the Main Ultrasound Program from LabVIEW and then open up the 
Main Ultrasound Program.vi. 
3. Using the open file program, choose a directory path in which the data should be 
saved by opening the folder path, selecting which folder to save the data in, and 
hitting select current directory. 
4. To active Time Response, select button next to “Capture waveform on set time 
interval” and set the interval and number of time points to acquire. 
5. Hit run button to begin Time Response. 
6. To view the results when completed, go to the Analyze Data tab, select Export 
Calculated Text and chose a folder to save the data to. 
7. To view results, open up the time data file using Excel and for each minute the 
enhancement will be given in mV and dB.  
 
 
 
  
 
 
 
 
 137
Appendix D: Coulter Counter Data 
 
Microbubble size and microbubble count per mg were measured with a Coutler 
Multisizer II.  Microbubbles were diluted to 0.002mg in electrolyte and were drawn 
through a 30μm aperture. Particles displace their own volume, increasing the impedance 
of the aperture. Coulter Principle states that the pulse is directly proportional to the 
volume of the particle that produced it. The overall size range measurable with the 
Coulter Counter is 0.4μm to 1200μm. Each result given by the Coulter Counter is 
displayed graphically as a percentage of channel content, which can be selected to display 
measurements by volume(weight), number(population) or surface area. 
 
Basic Coulter Multisizer II Operating Instructions: 
1. Fill the buffer reservoir with Isoton II and empty the waste reservoir. 
2. Turn on the power to the electrical unit and the sample stand. Allow the 
instrument to warm up 10 minutes. 
3. Press SETUP and select manual. Verify that your settings for your count are 
correct. The manometer select should be set to 500μl. 
4. Check the diameter of the orifice that is located on the aperture tube. The 30-50 
micron tube is commonly used for microbubbles. 
5. Remove the blue solution and install a small plastic beaker containing Isoton. 
6. Turn the knobs from CLOSE to FILL and from COUNT to RESET. This allows 
the blue solution to be flushed from the aperture tube. Turn from RESET to 
COUNT and from FILL to CLOSE for the bottom knob. (Note: turn clockwise) 
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7. Press FULL. Remove the beaker containing Isoton and install sample after several 
inversions. (Note: Sample in PBS) 
8. Press reset in order to clear the screen and turn the knob from COUNT to RESET. 
The light in the sample stand should come on and the Mercury level should drop. 
Turn the knob from RESET to COUNT. The instrument will stop counting when 
500ul of sample pass through the orifice of the aperture tube. 
9. When finished counting, install the plastic beaker containing the blue solution and 
turn the knob from COUNT to RESET. Turn the knob from RESET to COUNT. 
Repeat 4X. 
 
Results of these measurements on PLA based microbubbles are presented in the figures 
D.1 and D.2. 
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Figure D.1: Coulter analysis. Size distribution of PLA microbubbles by (A) number (population)- mean 
diameter 1.45 μm, and (B) volume (weight)- mean diameter 4.53μm.  
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Figure D.2: Coulter analysis results. For 0.002mg of PLA microbubbles there were approximately 70,000 
microbubble counts. Therefore there are approximately 35,000,000 microbubbles/mg of the PLA contrast 
agent.   
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Appendix E: Proof of Concept Drug Delivery Experiments 
 
This appendix describes the delivery of dye from surfactant blended microbubbles 
into 2D and 3D MDA-MB-231/MCF-7 cells.  
Microbubbles made with PEMA blends were ligated with GRGDS. The freeze-
dried bubbles were then labeled with a model for a membrane soluble drug; the cationic 
green dye DiOC2(3), (3,3’-diethyleneoxacarbocyanine iodide Mw 460.31 Da). A cationic 
dye was chosen due to negatively charged surface of the microbubbles.  
The protocol for the adsorbing the dye to the microbubbles is as follows. 100mg 
of dye was dissolved in 2.3ml of DMSO (2M), a 2ul stock was added into 18.9 ml MES 
for a 30mM solution. 10mM of the solution was incubated with 25mg of bubbles, and 
shook end over end for 30min, washed vigorously 3 times with MES and freeze-dried.  
To confirm fluorescence, bubbles were imaged under fluorescent microscope. As 
expected, the bubbles with the dye fluoresced, while the unlabeled bubbles did not (figure 
E.1, A&B).  
To determine if the dye on the bubbles would be taken up by cells, MDA-MB-231 
cells were grown in culture plates to 70% confluence and incubated with ligated dye-
labeled bubbles, unligated dye-labeled bubbles, and bubbles without dye. As seen in 
figure (E.1, C&D) the dye from the bubbles is delivered to the membranes of the cells, 
while there was no fluorescence from the control cells incubated with unlabeled bubbles 
(not shown). This was true for all bubbles with various surfactant blends. There was no 
significant difference noted between experiment groups in regards to amount of dye 
delivered to cells. The dye was uptaken by the cells in a similar manner with both ligated 
and unligated populations of bubbles, therefore it was concluded ligation was not 
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essential for uptake. The model cationic dye was released from the bubbles regardless of 
ligation.  
Tumors made of both MDA-MB-231 and MCF-7 cells were grown in vitro in a 
3D bioreactor with the assistance of A. Vamvakidou. Tumors were incubated with 
microbubbles that were conjugated with targeting vector GRGDS and labeled with the 
model dye. Pictures were taken using a fluorescent microscope at 0, 10 and 20 mins. As 
seen in figure (E.1, E) GRGDS ligated microbubbles were present on the tumor and also 
released dye that was taken up into the tumor cells, figure (E.1, F). It should be noted 
however that specific binding due to GRGDS ligation could not be confirmed; the control 
of unligated bubbles were also present on the tumors. There was no noted difference due 
to type of surfactant used in fabrication. All tumors incubated with bubbles labeled with 
dye became fluorescent.  
This is a proof of concept that a dye adsorbed to the bubbles ligated with GRGDS 
can be uptaken by cells. 
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Figure E.1: Fluorescent Micrographs. A) Bubbles labeled with cationic dye, light microscopy: inset, under 
fluorescent microscopy B) Unlabeled bubbles, light microscopy: inset, under fluorescent microscopy 
demonstrating fluorescence in dye labeled bubbles only. C) Light microscopy of MDA-MB-231 cells 
incubated with 0.5mg/ml dye labeled microbubbles, 10 minutes. D) Fluorescent microscopy of MDA-MB-
231 cells incubated with 0.5mg/ml dye labeled microbubbles, 10 minutes demonstrating uptake of dye from 
bubbles into membranes of cells. E) Light micrograph of MDA-MB-231/MCF tumors incubated with 
0.5mg/ml dye labeled microbubbles, 20 minutes F) Fluorescent micrograph of MDA-MB-231/MCF tumors 
incubated with 0.5mg/ml dye labeled microbubbles, 20 minutes demonstrating presence of bubbles and 
uptake of dye into tumors in vitro. Size bars = 50 microns. 
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Appendix F: Dose Response of PLA contrast agent insonated at 2.25, 5, 7.5 and 10 
MHz  
 
Dose response tests were performed using PLA microbubbles prior to (figure F.1) 
and after modification with GRGDS peptide (figure F.2) at the frequencies 2.25, 5, 7.5 
and 10 MHz. These results confirm that 5MHz is an appropriate insonation frequency for 
the in vitro characterization of the contrast agents both before and after ligand 
conjugation. 
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Figure F.1: Dose response curves of unmodified PLA contrast agent insonated at 2.25, 5, 
7.5 and 10 MHz. n=3, ± standard error of the mean  
 
 145
0
5
10
15
20
25
0 0.075 0.15 0.225 0.3 0.375 0.45 0.525 0.6 0.675 0.75
Dose (mg/ml)
En
ha
nc
em
en
t 
(d
B)
   
 (n
t  2.25MHz
5MHz
7.5MHz
10MHz
 
Figure F.2: Dose response curves of GRGDS ligated PLA contrast agent insonated at 
2.25, 5, 7.5 and 10 MHz. n=3, ± standard error of the mean  
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she helped create two ideas for companies, Focus Therapeutics and Puragent, for which she 
authored business plans and represented at competitions, allowing her and her team to be awarded 
Grand Prize at the Drexel University Business Plan Competition as well as top positions in the 
Wharton Venture Finals Competition, MIT $100K Entrepreneurship Competition, the Purdue 
National Life Sciences Business Plan Competition, and Grand Prize in the Loring Entrepreneurial 
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